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1 Zusammenfassung 
 
Um den Mechanismus der Substrattranslokation von Transportern durch die Membran 
zu verstehen, sind Studien betreffend deren Struktur und die Funktion unerlässlich. 
Unser Labor beschäftigt sich seit längerem mit einem prokaryotischen Mitglied der 
Peptid Transporter (PTR) Familie von Symportern. Diese Familie ist für den 
Transport von Di- und Tripeptiden in die Zelle verantwortlich, transportiert aber auch 
Medikamente und peptid-ähnliche Stoffe. Die Strukturbestimmung von 
Membranproteinen ist ein schwieriges Unterfangen, deshalb wurden zwei Strategien 
verfolgt, um die Struktur von YdgR zu lösen.     
 
Es wurde bereits gezeigt, dass Co-Kristallisation von Membranproteinen mit 
monoklonalen Antikörperfragmenten (mFab) in gut streuenden Proteinkristallen 
resultierten können [42]. Die Detergentmizelle schirmt den Grossteil des 
solubilisierten Membranproteins ab, was zur Beschränkung von zugänglichen 
Bereichen führt, die Kristallkontakte formen könnten. Im Komplex mit mFab 
Fragmenten werden diese Bereiche vergrößert und erhöhen die Wahrscheinlichkeit 
von gut geordneten Proteinkristallen. Deshalb wurden zwei konformationspezifische 
Antikörper gegen YdgR generiert, um sie für Co-Kristallisation zu nutzen. Die 
resultierenden Kristalle streuten bis 8-10 Å.  
 
Ausserdem wurde gezeigt, dass die erhöhte Thermostabilität von Proteinen die 
Wahrscheinlichkeit für gut streuende Kristalle verbessert [52]. Nach der Mutagenese 
von YdgR [35] wurden die Mutanten mit einer „high-thoughtput“ Methode auf ihre 
Thermostabilität getestet. Zwei Mutanten, deren Thermostabilität um wenigstens 3°C 
erhöht war, konnten identifiziert werden. Ein weiter Assay, der auf der Fraktion von 
gefalteten Protein nach einer Inkubation auf 50°C basiert, konnte zeigen, dass sowohl 
die Einzelmutanten als auch die Doppelmutante erhöhte Thermostabilität zeigen und 
ihre Toleranz für raue Detergentien wie LDAO erhöht ist. Unglücklicherweise 
formten die Mutanten keine Kristalle. Der Vergleich der Mutanten mit dem PTR- 
Transporter PepTso, dessen Struktur bereits gelöst ist [39], zeigte, dass selbst nach der 
Selektion von thermostabilen YdgR Mutanten aus E. coli, diese weniger thermostabil 
sind als das Homolog PepTso aus Shewanella oneidensis.  
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Interessanterweise kann einer der Antikörper nur mit dem N-terminal His-tag nativen 
YdgR interagieren, während der zweite mAb auch mit allen Mutanten unabhängig 
von der Orientierung des His- tags interagieren kann. Wahrscheinlich können die 
thermostabilien Mutanten nur eine Konformation annehmen, in der das Antigen des 
ersten mAb nicht zugänglich ist. Um dies Annahme zu überprüfen, wurde die 
zugänglichen Lysine im nativen Protein und in den Mutanten acetyliert und das 
Acetylierungsmuster mit Massenspektrometrie analysiert. Die thermostabilen 
Mutanten scheinen hauptsächlich die „in-ward facing“ Konformation anzunehmen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   5 
2 Abstract  
 
Structural and functional studies on transmembrane transporters are crucial to 
understanding mechanisms of substrate translocation. Our lab has begun structural 
studies on YdgR, a prokaryotic member of the peptide transporter (PTR) family of 
symporters. This transporter family takes up di-/tri-peptides, as well as many drugs 
and peptidomimetics. As membrane protein crystallization is inherently difficult, two 
strategies were used to approach this problem.  
 
First, it has been shown that co-crystallization of monoclonal antibody (mFab) 
fragments with membrane proteins can give rise to well diffracting crystals [42]. Due 
to the detergent micelle surrounding the protein, membrane proteins have restricted 
accessible areas that are able to form crystal contacts. When in complex with mFab 
fragments, the accesible surface area is increased and supports the formation of 
crystal contacts. Therefore two conformationally specific monoclonal antibodies 
against YdgR were produced to use as tools to improve crystallization. Co-
crystallization of the target protein YdgR with the proteolytically generated mFab 
fragments gave rise to crystals that diffracted to 8-10 Å. 
 
Second, improvement of protein thermostability has been shown to increase the 
probability of yielding crystals of membrane proteins [52]. Random mutatagensis of 
YdgR was carried out [35] and testing for thermostability of the target protein was 
performed in a high-throughput manner to identify mutants that are more 
thermostable and therefore may have a higher propensity to crystallize. Two mutants 
with an increase in thermostability of at least 3° C were identified. An additional 
thermostability screen, based on gel filtration analysis of the fraction of folded protein 
remaining after incubation at 50°C, revealed that the single mutants as well as a 
double mutant show increased thermostability and increased tolerance to the harsh 
detergent LDAO. Unfortunately the mutants did not give rise to crystals. Comparison 
with the PTR transporter PepTso, whose structure has been solved [39], shows that 
even after selection for thermostability the mutants of YdgR from E.coli are less 
thermostable than the homologue PepTso from Shewanella oneidensis. 
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Most interesting, one of the generated mAb is only able to interact with N-terminally 
His-tagged native YdgR while the second mAb interacts with the native protein as 
well as with the mutants, independent of the location of the His-tag. This suggests that 
the thermostable mutants are locked in one conformation, in which the antigen 
recognized by the first mAb is not exposed. Acetylation of accessible lysine residues 
coupled with analysis via mass spectrometry indicates that the thermostable mutants 
S166G and N196K may be locked in the inward facing conformation. Additional 
experiments to support this conclusion are underway. 
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3 Introduction 
 
3.1 Transport across membranes 
 
The barrier function of membranes is crucial for life since the membrane-enclosed 
compartments allow for the build-up of differences in solute concentrations that are 
necessary for driving metabolic processes. These differences form the basis for the 
intra- or extra-cellular gradient or gradients. Small hydrophobic molecules (O2, CO2, 
N2…) can freely traverse the membrane while larger molecules and especially 
charged molecules and ions have to be transported across this barrier in a passive or 
active manner depending on the physiological needs of the cell.  Controlled signal 
transfer and exchange of solutes with the environment and between cell compartments 
can be achieved by a wide variety of membrane proteins that have evolved to serve 
different tasks, such as exchange of nutrients and metabolic waste products or ions 
necessary for the cell’s membrane potential (Figure 3.1).  
Channels and carrier proteins (also known as carriers or permeases) allow the 
transport of solutes that are normally not able to cross the membrane due to their size 
or charge. Channels and many carrier proteins facilitate transport “downhill”, or in the 
direction of the solute gradient, and therefore no energy input has to be used to feed 
this passive transport. Channels can be open or closed and serve as selective filters 
across the membrane.  
On the other hand there is also a variety of active transporters that use energy either in 
the form of ATP, from coupling with gradients, from redox processes in 
mitrochondria, or from light for transport [2].  
 
Figure 3.1: Schematic figure of passive and active transport 
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3.2 Primary active transporters 
 
For active transport energy is needed to transport substrate across the membrane 
against the substrate gradient in an “uphill” manner. These transporters are also 
known as primary active transporters. [37] Depending on the source of energy used 
different forms of transporters can be distinguished.  
 
Some transporters, such as bacteriorhodopsin in archae use energy in the form of light 
for proton transport, but ATP-driven transport is widely used in all organisms.  
Two major groups of transporters use ATP-driven transport, namely ATP-binding 
cassette (ABC) transporters and P-type ATPases. Vacuolar H+ ATPases (V-type 
ATPases) also use ATP to pump protons across membranes.  
 
ABC-transporters consist of two transmembrane domains (TMD) and two 
cytoplasmic nucleotide-binding domains (NBD) (Figure 3.2b). While the TMDs form 
a passage-way through the membrane, the NBDs can bind and hydrolyze ATP. The 
NBDs come close together and form two ATP binding sites when ATP is available, 
but undergo a conformational change when ATP is hydrolyzed to ADP. This 
conformational change due to ATP hydrolysis is transferred to the TMDs via 
connecting helices that seem to underlie a conserved architecture. [21] Since ABC 
transporters are linked to hereditary diseases, such as cystic fibrosis, and also play a 
role in extrusion of chemotherapeutic drugs, they are of high interest what is reflected 
by the high number of solved crystal structures [21].  
 
Prominent members of the group of the P-type ATPases are the Sodium-Potassium 
pump that is crucial for establishing the gradient of sodium and potassium ions across 
the cell membrane and the Ca2+ pump, which together consume one third of the 
energy used in humans [41]. These pumps consist of three cytosolic domains: N 
(nucleotide binding), P (phosphorylation) and A (actuator) together with a 
transmembrane domain (TMD) varying in the number of transmembrane helices 
depending on the subtype (Figure 3.2a). The phosporylation and dephosphorylation of 
the P domain leads to a major rotation of the A domain, which is transferred to the 
TMD that provides the opening and closing of a transport cavity [37].  
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Many primary active transporters use ATP to set up a gradient of ion and/or solute 
gradients whose free energy can be used by secondary active transporters.  
 
 
Figure 3.2: Schematic drawing of a. the Na/K pump and b. the maltose ABC transporter; modified 
from Oldham et al. 2007 and Morth, Pedersen et at. 2011 
 
3.3 Secondary active transporters 
 
Secondary active transporters are widely spread through all kingdoms of life. They 
transport a wide variety of compounds. Accumulation of the transported substrate is 
achieved by coupling the transport with co-transport of another ion or solute down its 
concentration gradient. In that way the free energy of another gradient is used to 
transport the target substrate.  
 
Secondary active transporters can act as symporters or antiporters. Symporters 
translocate two or more substrates in the same direction, making use of the gradient of 
one substrate, while antiporters transport two or more substrates in opposite directions 
[30]. The general model of secondary active transport is based on the alternating 
access hypothesis. The transporter undergoes conformational changes that provide 
alternating pathways on either side of the molecule. These conformations include at 
least an inward-facing and an outward-facing, and a transition state (Figure 3.3), 
which provides no pathway to either side [21].  
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Figure 3.3: Alternating access model (transporter in yellow and substate in blue) 
 
The secondary active transporters seem to be based on a common transport 
mechanism since similar features in transmembrane helix packing can be observed 
(Figure 3.4). The structures of a growing number of secondary active transporters 
have been solved in the last years. Nearly all of them have inverted repeats that are 
parallel or anti-parallel, which seems to be a common feature [14; 47; 62; 63]. In all 
known structures so far, helix bundles are related by a pseudo-two-fold axis located in 
the plane of the membrane despite the lack of detectable sequence conservation [63].  
 
 
Figure 3.4: Inverted repeats with pseudo-2-fold axis indicated in coloured triangles or trapezoids; 
Topology of a. BetP b. vSGLT c. Mhp1 d. LeuT; Figure modified from Ressl et al. 2009; Faham et al 
2008; Weyand et al. 2008 and Yamashita et al. 2005 
 
3.4 Comparison of Sodium-coupled secondary active 
transporter structures  
 
Unfortunately most structures of individual secondary active transporters are only 
available in the inward-facing, outward-facing or the substrate occluded–state. To 
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learn more about the transport mechanism structures of different proteins must be 
compared. The structures of several sodium-coupled secondary transporters are 
available. The comparison of the structure of outward-facing LeuTAa [63], outward-
facing Mhp1 [62], inward- facing vSGLT [14] and BetP in an inward-facing occluded 
state [46] proposes a mechanism of transport. The rotational movement of a central 
four-helix bundle occludes the substrate-binding site to change from an outward-
facing conformation to an occluded state. The helices in the scaffold surrounding the 
four helix-bundle straighten and open a passageway for the substrate resulting in an 
inward-facing conformation. Therefore the conformational changes necessary for 
transport can be described as concerted movements of the four-helix bundle and the 
surrounding scaffold [46].  Most interesting, conserved glycine residues are located 
close to the pivot points of movement and seem to provide the necessary flexibility 
[46].  
 
 
Figure 3.5: Bundle and scaffold (Pseudo-2-fold axis as green arrows); modified from Forrest and 
Kramer et al. 2010 
 
The only secondary active transporter whose structure in both the inward and the 
outward-facing conformation is available is the sodium/aspartate symporter GltPh 
from Pyrococcus horikoshii [47].  The outward-facing structure of GltPh was already 
solved [64], while cysteine crosslinking was applied to solve the structure of GltPh 
locked in an inward-facing conformation.  
Comparison of the inward and the outward–facing conformation proposes a 
mechanism of transport. GltPh forms a trimer and therefore some parts of the protein 
make intermolecular contact while another part forms a relatively rigid transport 
domain. Conversion of the outward- to the inward-facing conformation involves 
movement and rotation of the transport domain towards the peripheral trimerization 
scaffolding helices. This movement is permitted by the partial unwinding and 
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refolding of helices connecting the transport domain with the scaffold domain. This is 
facilitated by conserved glycine residues, which allow the unfolding/refolding events 
and may serve as hinges. The gating mechanism is based on the movement of two 
hairpin helices (HP1 and HP2) that close the intra- or extracellular gate [47].  
Therefore the rotational movement of a flexible domain against a stable scaffold 
seems to be a general feature of the transport mechanism of secondary active sodium 
driven transporters.  
 
In general, discontinuous helices and hairpin helices can be found in many secondary 
active transporters as well as in ion pumps [49]. These motifs seem to be connected 
with the ion translocation function, and ensure that the ion binding site is deeply 
buried in the non-polar membrane core. Ion desolvation is therefore necessary and 
ensures high selectivity of binding [49].  
 
3.5 Proton- driven secondary active transporters 
 
Most secondary active transporters are coupled to a proton or sodium gradient [56]. In 
comparison with sodium-coupled secondary active transporters only a few structures 
of proton-driven transporters have been solved. One of the solved structures is the 
structure of the well-characterized lactose permease LacY.  
 
3.5.1 LacY  
 
LacY belongs to the major facilitator superfamily (MFS). It carries out the coupled 
transport of a galactoside with a proton. LacY is selective for disaccharides containing 
a D-galactopyranoyl ring as well as D-galactose, but has no affinity for D-
glucopyranoside or D-glucose [19]. The transport mechanism was extensively studied 
with different methods, but unique insight was gained when the structure of the LacY 
mutant C154G was solved in the inward-facing conformation [1]. The structure of 
native LacY has also been solved and shows the same inward-facing conformation 
[20]. LacY consists of 12 transmembrane helices that form an N- and a C-terminal 
six-helix bundle positioned by a pseudo-2-fold symmetry axis running perpendicular 
to the membrane, connected with a long loop between helix VI and VII [1] (Figure 
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3.6). In the structure LacY C154G, a lactose analogue, β-D-galactopyranosyl-1-thio-
β-D-galactopyranoside (TDG), is bound to the transporter [1]. This revealed the 
residues involved in substrate binding (Figure 3.6).  
 
                          
Figure 3.6: a. LacY structure with N-terminal six-helix bundle (blue and green) and C-terminal six-
helix bundle (in yellow and red); b Substrate binding site in LacY; both modified from Abramson et al. 
2003  
 
Arg-144 interacts with the O3 and O4 atoms of the galactopyranosyl-ring via a 
bidentate hydrogen bond.  Glu–126 may interact with the O4, O5, O6 of the 
galactopyranoside ring via water molecules. The indole ring of Trp-151 interacts with 
the bottom of the galactopyranosyl ring. Glu-269 forms a salt bridge with Arg-144 
[1]. A model for transport was proposed that is based on biochemical data and 
modeling of the outward-facing conformation by a rotation of the N-and the C-
terminal helix bundle [1; 19] (Figure 3.7).  
 
Figure 3.7: Proposed transport mechanism of LacY modified from Abramson et al. 2003; 
Conformation of the solved structure is marked with a rectangle. 
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The outward-facing form is protonated and the proton is shared between Glu-269 and 
His-322. A galactoside is recognized by Trp-151, Arg-144 and Glu-126, which 
disrupts the salt-bridge between Arg-144 and Glu-126 and brings His-322 in contact 
with Glu-325. Glu-269 is recruited to the binding site and forms a salt-bridge with 
Arg-144. This process may cause the rapid transition to the inward-facing 
conformation [19]. After the release of the substrate, the salt-bridge between Arg-144 
and Glu-126 is formed again. The proton is released from Glu-325.  
 
3.5.2 Comparison of LacY with FucP and GlpT 
 
Two other transporter structures belonging to the MFS family are available. The 
structure of the E. coli Glycerol-3-phosphate transporter GlpT was solved in 2003 
[22] while the structure of the E. coli fucose/H+ symporter FucP was solved recently 
[8].  
 
Based on the structure of LacY in an inward-facing conformation and GlpT in an 
inward-facing conformation, a general mechanism for the transport mechanism of 
MFS family was proposed. The binding site has access to each side of the membrane 
in an alternating fashion based on the N-terminal and C-terminal helix bundles 
moving back and forth. This model is called the rocker-switch mechanism. Unlike the 
transport mechanism for the sodium-coupled transporters (see chapter 3.4), these 
transporters do not form a passageway for transport but rather regulate access of the 
substrate-binding site to the cytoplasm or the periplasm.  
Biochemical data suggest that the formation and breakage of intra and intermolecular 
salt-bridges are essential for the control of helical movements in GlpT that are 
necessary for the inter-conversion of inward- and outward-facing conformations [29]. 
This formation and breakage of salt-bridges can also be seen in the substrate binding 
site in LacY [1].  The structure of FucP was solved in the outward-facing 
conformation. Again the N- and C-terminal helix bundles show a pseudosymmetrical 
2-fold axis connected by a long flexible linker. The comparison of LacY and FucP 
suggests that rigid body rotations are the basis for the interconversion of the inward 
and the outward-facing conformation [8], supporting the rocker switch mechanism 
model (Figure 3.8). 
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Figure 3.8: Model of inward facing FucP derived from rigid body rotation; modified from Dang, Sun et 
al 2010 
 
3.5.3 Peptide Transporter (PTR) family 
 
While in prokaryotes and simple eukaryotic cells transport processes are mainly 
driven by proton gradients, in higher eukaryotes the major driving force comes from 
sodium gradients [9]. Nevertheless some transport processes in higher eukaryotes are 
still dependent on proton force [9].  
A representative proton carrier system is the Peptide Transporter (PTR) family, which 
transports di-and tri-peptides into the cell. The PTR family belongs to the major 
facilitator superfamily (MFS), together with many other proton-coupled transporters 
[7]. 
This proton-dependent group of peptide transporters can be found in organisms 
ranging from bacteria to humans. In mammals, two proteins of the PEPT series can be 
found that transport exclusively di- and tri-pepides [9]. The mammalian intestinal 
transporter is called PEPT1 while the renal isoform is known as PEPT2.  
 
Although peptide transporter homologues differ greatly in sequence and size small 
protein stretches are highly conserved [9]. These conserved regions are called PTR 
motifs and two are located on the outward facing end of the first transmembrane 
domain (TMD) and between TMD2 and 3 respectively (Figure 3.9). The third motif in 
TMD5 shows absolute conservation among all members of the PTR family [9]. For 
PepT1 and PepT2 analysis of single point mutations suggests that TMD2 to 5 and 7 
play an important role in substate affinity and the transport mechanism [9; 26; 27] It 
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was also shown that a single mutation of tyrosine 167 in human PepT1 to alanine 
completely abolished transport activity [65].  
 
Figure 3.9: Conserved motifs in the PTR family; Y167 is marked in dark green; Figure modified from 
Daniel, Spanier et al 2005 
 
Most interesting, the family of di- and tri-peptide transporters transports a variety of 
substrates. Despite its preference for peptides made of L-α amino acids and a size 
limitation to di- and tri-peptides, it also transports a variety of peptidomimetics such 
as b-lactam antibiotics and other drugs [9]. This special and quite unique substrate 
variety make this family an interesting target for further studies.  
Since the homologues of the PTR family can be found from bacteria to man, 
prokaryotic homologues of mammalian transporters can be studied to understand the 
mechanisms of transport underlying the whole family of transporters.  
 
3.5.4 Crystal structure of a prokaryotic homologue of mammalian 
PepT1 and PepT2 
 
Recently the structure of a prokaryotic homologue of mammalian PepT1 from 
Shewanella oneidensis, called PepTso, was solved [39] in an occluded state and gave 
new insight into the transport mechanism of the MFS family. The transporter consists 
of 14 transmembrane helices that form an N- and a C- terminal six helix bundle 
related by a pseudo-2-fold axis (Figure 3.10 a). Two helices, namely HA and HB, are 
inserted into the cytoplasmic loop connecting the N- and the C-terminal halves. In the 
structure a central and a smaller extracellular cavity are visible. The central cavity is 
closed to the cytoplasm by an intracellular gate formed by side-chain interactions of 
residues in two helix hairpins formed by helices 4-5 (N-terminal bundle) and helices 
10-11 (C-terminal bundle).  
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Figure 3.10: a. Topology of Peptso; b. Superposition of PepTso (green, yellow, red) and LacY (cyan) 
viewed from the intracellular side; modified from Newstead, Drew et al. 2001 
 
The residues forming this intracellular gate are highly conserved in vertebrate peptide 
transporters including Leu327, Tyr154 and Phe150.  Tyr154 and Phe150 belong to the 
highly conserved PTR2 motif. The central cavity is closed towards the external cavity 
by helix 1 (H1), H2, H7 and H8 that pack tightly together.  
The central cavity has dimensions suitable to accommodate di- or tri-peptides and 
could include the binding site since the comparison with LacY shows the binding site 
at a similar location. On the surface of the central cavity several conserved resiudes 
can be found: Arg25, Arg32, Lys127, Tyr29, Tyr 68, Glu419, Ile157, Trp312, 
Phe315, Trp446 and Ser423. A variety of potential hydrogen-bond donors and 
acceptors seem to be necessary to support the transport of a diverse spectrum of 
substrates.  
The His57 residue was shown to be the primary protonation site in human PepT1 and 
PepT2. The respective residue His61 is buried in the extracellular gate of the central 
cavity while the homologous residue is completely exposed in the inward-facing 
conformation in LacY.  
Superposition of LacY and PepTso shows that the major changes from the occluded 
form to the inward-facing conformation are observed in the C-terminal bundle 
especially in the sub-bundle C1 (Figure 3.10b). This observation indicates that the N-
terminal helix bundle is less dynamic than the C-terminal bundles, which contain the 
mobile gates. This would undermine the model of a rocker-switch mechanism since 
there would be a functional division in the helix bundles [17; 39]. 
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3.5.5 The E. coli homologue YdgR 
 
In addition to ABC transporter systems that transport di-peptides or oligopeptides, a 
tri-peptide permease (tppB) is responsible for the uptake of di- and tri-peptides in S. 
typhimurium [18]. By locus analysis the YdgR protein was identified as the 
corresponding tppB system in E. coli [9]. Electron microscopy experiments with 
detergent-solubilized YdgR suggest a monomeric form [61].  
Substrate specificity resembles that of mammalian PepT1 [61].  
Therefore studies of the E.coli homologue YdgR provide also insight into the 
transport mechanism of the PTR family in higher organisms. Since the structural 
information of transporters is still limited, YdgR was chosen as the target protein for 
crystallizaton trials to learn more about the underlying processes of transport. Since 
membrane protein crystallization is still challenging, different strategies such as co-
crystallization with monoclonal antibody fragments (mFabs) and the generation of 
thermostable mutants was applied to facilitate crystallization.   
 
3.6 Crystallization of membrane proteins 
 
The general importance of membrane proteins is shown by the fact that more than 20-
35% of all open reading frames of currently known genomes encode for membrane 
proteins, and more than 70% of all known pharmacological targets are membrane 
proteins [16]. That makes the need for more structural information concerning 
membrane proteins quite clear. The first structure of a membrane protein, namely the 
photosynthetic reaction center of the purple bacterium Rhodopseudomonas viridis, 
was solved in 1984 and showed that membrane proteins structures can be solved with 
general X-ray crystallography methods. Despite progress in expression, purification 
and crystallization techniques, structure determination of membrane proteins is still 
quite challenging. Structures of less than 250 unique membrane proteins are solved 
[5], and almost all of them are from bacteria or yeast. 
The main problems of crystallizability of membrane proteins are due to their 
amphipathic character, which is an intrinsic property of membrane proteins. They 
reside in the lipid membrane with polar regions extending into the surrounding 
solvent. Detergent has to be used to extract them from the membrane and keep them 
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soluble in aqueous solvent. However, detergents directly affect protein stability and 
homogeneity [16]. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Different types of membrane protein crystals 
 
In Figure 3.11 the different forms of membrane protein crystals are shown. While 2-
dimensional (2D) crystals are prepared by the exchange of membrane proteins into 
lipid bilayers and are used for electron microscopy studies, 3D crystals require the 
protein to be extracted from the membrane via detergents. Type I 3D crystals are 
stacks of 2D crystals stabilized by protein-protein and protein-lipid interactions. 
Lipidic cubic phase, a three dimensional continous lipid phase, can be used to 
generate this kind of crystal but the underlying mechanism of how crystals form in the 
lipidic cubic phase is not known.  
Some structures, including that of rhodopsin, have been solved with this technique. 
However, the technique is technically difficult and most probably not suitable for the 
whole variety of membrane proteins. 
 
Type 2 3D crystals form from detergent-micelle incorporated proteins. Crystal 
contacts are exclusively formed by polar headgroups that are not shield by the 
detergent micelle. Therefore they often have a high solvent content of 65-80%. Due to 
limited contacts in the crystal lattice, Type 2 3D crystals are often poorly ordered and 
may not diffract well enough to be used for determination of structural information. 
[16; 25] 
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Figure 3.12: A membrane protein within micelles made of maltosides with different alkyl chain length; 
Modified from Kunji et al. 2008 
 
The choice of detergent plays a main role in crystal quality. The longer the detergent 
molecules, the larger the crystal micelle and the less surface area is accessible for 
crystal contacts, resulting in poorly diffracting crystals (Figure 3.12). However, 
detergent with longer chain length is better tolerated by membrane proteins, since 
shorter detergent exposes larger parts of the protein, increasing the tendency for 
crystal formation.  
As shown in figure X, detergents of different sizes expose varying amounts of surface 
accessible areas. While dodecyl maltoside (DDM, 12M) covers the whole protein 
leaving no exposed areas for crystal contact, nonyl maltoside (NM, 9M) may form a 
micelle too small to accommodate the hydrophobic parts of the protein and may 
promote aggregation.  
To increase the tendency of membrane proteins to give rise to well-diffracting 
crystals, two general strategies can be used. First the surface accessible area available 
for crystal contact formation can be increased by co-crystallization with a monoclonal 
Fab fragment as described in [24] Second, the protein’s intrinsic stability can be 
improved by mutagenesis to increase the tolerance for short chain-length detergents 
[52].  
 
3.7 Increasing surface-accessible area with Fv or mFab 
fragments  
 
Enlarging the polar surfaces of membrane protein-detergent complexes can increase 
the probability of obtaining well-ordered Type II 3D crystals. This can be achieved by 
co-crystallization with conformationally-specific monoclonal antibody (mFab) 
fragments [42]. Native antibodies are not suitable for this purpose since they have 
flexible linker regions. However, proteolytically generated mFab fragments can be 
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used for co-crystallization with membrane proteins. Nevertheless proteolytic cleavage 
can generate heterogeneous results. 
Recombinant antibody fragments can be generated in the Fv or the Fab form. 
Generation of the Fv form includes the time-consuming cloning of encoding genes 
from hybridoma cell lines or direct selection for recombinant fragments from phage 
display libraries or by ribosomal display [24].  
 
Screening strategies from hybridoma fusion of monoclonal antibody libraries should 
give rise to mAb or antibody fragments that recognize the native conformation of the 
target protein. Therefore the selected mAb fragment should be ELISA-positive but 
Western blot-negative. In the ELISA the protein-detergent complex should be 
presented in a native conformation, for example bound to a Nickel-chelating matrix 
via a His-tag [24]. 
 
The crystal structure of cytochrome c oxidase (COX) from Paracoccus denitrificans 
was the first example that showed the feasibility of co-crystallization of an antibody 
fragment with a membrane protein [42]. The yeast cytochrome bc1 complex was also 
crystallized with an antibody Fv fragment [23].  
 
 
Figure 3.13: a. Crystal lattive of yeast cytochrome bc1 (blue and green) with Fv fragment (red); Crystal 
lattive of KscA channel (blue and geen) in complex with mFab fragment (red and yellow) top view (b) 
and side view (c); modified from Hunte and Michel 2002 
 
In these structures the main crystal contacts are made by the Fv-fragments (Figure 
3.13). Although the multisubunit complex cytochrome bc1 has large hydrophilic 
domains on both sides of the membrane, only co-crystallization with the antibody 
fragment gave rise to well-diffracting crystals [24].  
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The structure determination of the KscA potassium channel-Fab fragment complex 
provided the first example of an integral membrane protein co-crystallized with a Fab 
fragment [68]. The crystal of the complex diffracted better than the crystals of the 
channel alone [12] giving more insight into the transport mechanism of KscA. 
Additionally the Fab fragments could be used for solving the phase via molecular 
replacement. 
Crystal contacts of the channel-Fab-complex are exclusively made by the Fab 
fragment. Compared to the Fv, the size of the Fab is more suitable for co-
crystallization experiments with integral membrane proteins that have no large 
hydrophilic domains protruding form either side of the detergent micelle [24].  
 
3.8 Thermostable mutants  
 
A common problem of membrane proteins is their low stability in the detergent-
solubilized form. After they are removed from the membrane, membrane proteins 
often undergo rapid unfolding and inactivation [6]. Despite the efforts to stabilize 
proteins with lipids or substrate, a higher stabilization effect is often required.  
Studies on directed evolution and targeted mutagenesis have shown that quite a high 
percentage of mutations stabilize membrane proteins and that more stable membrane 
proteins can be generated [6; 15; 28; 66]. An additional advantage could be reduced 
conformational flexibility due to these stabilizing mutations. Decreased flexibility can 
lead to decreased protein sample heterogeneity and increase the probability of 
successful structure determination. 
Previous publications have shown that membrane proteins can be stabilized by 
mutagenesis. One of the first examples was a mutation in the lactose permease LacY. 
The C154G mutant shows decreased conformational flexibility [54] and increased 
thermostability [55], both assumed to be advantageous for crystallization trials. 
Indeed, the structure of C154G [1] was solved before that of the native transporter 
LacY [20] .  
Another example is the determination of the structure of the β1-adrenergic receptor 
[60]. Alanine-scanning mutagenesis identified six point mutations that stabilized the 
target protein by 21°C [52]. Additionally these mutations seem to decrease 
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conformational flexibility since the mutant has a clear preference for the antagonist. 
This stabilization also goes hand in hand with improved stability in a variety of 
detergents.  
Similar effects can be observed for the adenosine A2a receptor. Several mutations 
were identified that stabilize the receptor in a distinct conformation, either antagonist 
or agonist bound [31; 34]  
 
Therefore random mutagenesis might result in thermostable mutants. Since increased 
thermostability seems to go hand in hand with decreased confomational flexibility, 
these mutants might be promising to give well-ordered and diffracting crystals for 
structure determination.  
 
3.9 Objectives of this study 
 
 
Beside crystal trials with native YdgR, two different strategies were tested to facilitate 
the formation of well-diffracting crystals. First, two monoclonal antibodies were 
generated to use them for co-crystallization trials with YdgR. Second, thermostable 
mutants could be useful for structure determination of YdgR. Our lab has identified 
35 single point mutations of YdgR that result in partial or complete loss of activity 
serving as potential targets for crystallization [35]. 16 of these loss-of-function 
mutants were tested for thermostability and their tolerance for harsh detergents and 
finally subjected to crystallization trials.  
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4 Materials and Methods 
4.1  Molecular Biology 
4.1.1 Transformation 
 
For all cloning procedures DH5α cells were used. For bacterial transformation, 100ng 
plasmid DNA was added to 50 ul competent cells and incubated on ice for 15 
minutes. Then a heat shock at 37°C was performed for one minute followed by 
incubation on ice for 2 minutes. 500 ul SOC medium (Table 4.2) were added and the 
cells were shaken for 30 minutes at 37°C on a table shaker at 1000 rpm. The cells 
were spun at 2000g and the pellet was resuspended in 100 ul SOC medium and plated 
on LB agar plates selective for the suitable antibiotic.  
 
Table 4.1: Bacterial strains 
 
       Strain    Genotype   
  
  DH5α      F-, supE44, ∆lacU169, [Φ80lacZ∆M15], 
hsdR17, recA1, endA1, gyrA96, thi-1, (res-
mod+), deoR 
  BL21(DE3)   F–, ompT, gal, dcm, lon, hsdSB(rB- mB+), 
λ(DE3 [lacI, lacUV5- T7, gene1, ind1, sam7, 
nin5])  
  C43(DE3)    F–, ompT, gal, dcm, lon, hsdSB(rB- mB+), 
λ(DE3 [lacI, lacUV5- T7, gene1, ind1, sam7, 
nin5])   
     Additionally at least two uncharacterized 
mutations [59] 
       XL10 GOLD Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
 
   25 
4.1.2 Agarose Gel electrophoresis  
 
To check quantity and purity of PCR or restriction digest products, the products were 
loaded on a 1% (w/v) agarose gel. 1 g agarose was dissolved in 100 ml hot TAE 
buffer (Table 4.2). After the suspension had cooled down to ca. 40°C, Sybr Safe 
DNA gel Stain (Invitrogen) was added in a ratio of 1: 10000 and the gel was poured. 
After polymerization the samples were loaded and the gel was run at 100 V in 1X 
TAE buffer. 
 
Table 4.2: Buffers and media 
 
 Buffer    Composition   
  
Luria Bertani (LB) medium 10 g tryptone, 5 g yeast extract, 10 g NaCl, 
adjusted to pH 7 with NaOH; dissolved in dH2O 
to 1000 mL and autoclaved 
LB Agar 15 g agar dissolved in 1000 mL LB medium 
SOB 20g tryptone, 5g yeast extract, 0.5g NaCl, 2.5mg 
1M KCl adjusted to pH 7 with NaOH; dissolved 
in dH2O to 1000ml and autoclaved; 10ml of  
sterile 1M MgCl2 added before use 
SOC SOB media containing 2% glucose 
10× TAE buffer 0.1 M Tris-HCl pH 8, 10 mM EDTA-Na2-salt, 
0.2 M acetic acid 
1× TE buffer  10 mM Tris-HCl containing 1 mM EDTA-Na2-
salt 
DNA loading buffer 30% (v/v) glycerol, 0.25% (w/v) bromophenol 
blue, 0.25% (w/v), 0.25% (w/v) xylene cyanol 
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4.1.3 Extraction of restriction digest after agarose gel electrophoresis 
 
A kit (QIAquick™ Gel Extraction Kit, Qiagen) was used for this purpose. The 
protocol was performed as instructed by the manufacturer. Extracted DNA was 
dissolved in 30ul TE buffer.  
 
4.1.4 Plasmid purification 
 
The plasmid was transformed into DH5α cells, plated on selective LB agar plates and 
incubated overnight on 37° C. A single colony was picked and inoculated in liquid 
selective LB medium and grown overnight at 37°C. The cells were harvested and a 
commercial kit (MiniPrep Kit, Qiagen) was used for plasmid purification. The 
protocol was performed as instructed by the manufacturer. The plasmid was eluted 
with 30 ul Elution Buffer. The DNA concentration was measured via absorbance at 
260 nm with a NanoDrop (ND-100) spectrophotometer.  The DNA sequence was 
verified using an in-house sequencing facility.  
 
4.1.5 PCR (Polymerase chain reaction) 
 
The standard volume of the PCR reaction was 50 ul. The PCR reaction contained 100 
ng template DNA, 1 unit Phusion Polymerase (Finnzymes), 2 ul of a 10 umol Primer 
mix, 1 ul of a10 mM dNTP mix, 10 ul of 5X reaction buffer.  
 
Table 4.3: PCR Protocol: Step 2-4 were repeated 25 times   
 
 PCR step    Temperature [°C]   Time   
 
 1. Initial denaturation  95°C    2 minutes 
 2. Denaturation   95°C     30 seconds 
 3. Annealing   55°C     30 seconds 
 4. Elongation   72°C    3 minutes 
 5. Final Elongation   72°C     10 minutes 
 
   27 
4.1.6 Site-directed mutagenesis 
 
For site-directed mutagenesis, forward and reverse primers with the desired mutation 
were designed. The PCR set-up is comparable to a standard PCR except Phusion 
Polymerase was exchanged with 2.5 units of PfuTurbo Polymerase (Stratagene). 
The template plasmid was digested with Dpn1 (Fermentas) for 1 hour at 37°C and 
transformed into DH5α cells. The cells were plated on selective LB agar plates. 10 
colonies were picked and grown in liquid LB culture. The purified plasmids were sent 
for genotyping to an in-house sequencing facility. 
 
4.1.7 Restriction Digest 
 
Restriction enzymes from Fermentas and New England Biolabs were used for 
restriction digests. Generally a double digest was performed. Therefore restriction 
reactions contained 5 units of restriction enzyme A, 5 units of restriction enzyme B, 5 
ul of suitable 10X restriction buffer and 2-5 ug DNA in a total volume of 50 ul. 
Additionally 1 unit of Alkaline Phosphatase (Fermentas) was added when vectors 
were digested. Alkaline Phosphatase removes 5’ phosphates to prevent self-ligation 
 
4.1.8 Ligation 
 
T4 DNA ligase (Roche) was used for ligation. The reactions contained 100-150 ng 
digested vector, insert in 5 times molar excess, 2 ul of 10X ligation buffer and 1 unit 
T4 DNA ligase in a total volume of 20 ul. The ligation buffer contains ATP, therefore 
more than 2 freeze and thaw cycles were avoided. The ligation reaction was incubated 
overnight at 4°C. The reaction was then transformed into DH5α and plated on LB 
agar plates with suitable selective antibiotic.  
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4.1.9 Cloned constructs 
 
All YdgR constructs were cloned into the pCS19 vector (kind gift from Michael 
Ehrmann, University Duisburg-Essen), in which protein expression is under the 
control of the T5 promoter [58]. The plasmid for PepTso expression pTTQ PepTso was 
a kind gift from Simon Newstead (Oxford University). The lacY and lacY C154G 
plasmids were a kind gift from H. Ron Kaback (University of California, Los 
Angeles). 
 
Table 4.4: Cloned constructs 
 
 Construct     Cloning strategy  
  
 C-term His6 YdgR              The full length ydgR gene was amplified 
from E.coli genomic DNA and cloned into 
the pCS19 vector using NcoI and BglII 
restriction sites.    
 N-terminal His10 YdgR TEV site           The ydgR gene was amplified from C-term 
His6 YdgR plasmid and cloned into a 
pCS19 vector with a N-terminal His10 tag 
that is cleavable with TEV protease. The 
restriction sites for BamHI and HinDIII 
were used.  
 N-terminal His10 YdgR TEV site (6-498)    Primers were designed for truncated version 
of YdgR and the PCR product was cloned 
into pCS19.   
 C-term His6 S166G                    Site-directed mutagenesis 
 C-term His S166G/N196K   Site-directed mutagenesis  
 N-terminal His10 S166G, TEV site         Site-directed mutagenesis  
 N-terminal His10 N196K,TEV site         Site-directed mutagenesis 
 N-terminal His10 S166G/N196K, TEV site Site-directed mutagenesis  
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4.2 Protein production and purification 
4.2.1 Expression of YdgR  
 
All YdgR constructs were over-expressed in E. coli C43(DE3) cells. The plasmids 
were freshly transformed and plated on LB agar plates selective for ampicillin 
resistance. Three 30 ml liquid pre-cultures were set up in 100 ml baffled flasks 
containing LB medium with 2% glucose and the selective antibiotic ampicillin at a 
final concentration of 100 ug/mL. The cultures were grown with shaking (220rpm) 
overnight at 37°C. On the next day the cells were harvested and resuspended in fresh 
medium. The cells were inoculated in 6 L fresh LB medium with 2% glucose 
containing the selective antibiotic ampicillin (100 ug/mL). The cells were grown with 
shaking (190 rpm) at 37°C to an OD600 of 0.4, and then the temperature was decreased 
to 18°C. When OD600 had reached a value of 0.6, the cells were induced with 0.1 mM 
IPTG. The expression was carried on overnight. The cells were harvested the next day 
and resuspended in 50 mM Tris at pH 8 containing 300 mM NaCl, 10% glucose and 2 
mM EDTA and stored at -20°C or -80°C.  
 
4.2.2 Expression of LacY and C154G 
 
The constructs were transformed into XL-10 GOLD cells and plated on LB agar 
plates containing the selective antibiotic ampicillin. 30 mL pre-cultures of LB with 
ampicillin in a final concentration of 100 ug/mL were grown with shaking (220rpm) 
overnight at 37°C in 100 ml baffled flasks. The next day the cells were harvested and 
inoculated in 2L LB containing ampicillin (100 ug/mL) in a 5L baffled flask. The 
culture was grown with shaking at 180 rpm at 37°C to an OD600 of 0.6 and then 
induced with 0.1-0.2 mM IPTG. Expression was carried out for 4 hours at 37°C.  
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4.2.3 Expression of PepTso  
 
The construct Peptso pTTQ was transformed into E. coli C43 (DE3) cells. Over-
expression was performed as described above for YdgR constructs except instead of 
LB medium containing 2% glucose TB medium was used.  
 
4.2.4 Membrane Preparation of YdgR, LacY and PepTso constructs 
 
All steps were peformed at 4°C or on ice. The harvested cells were resuspended in 50 
mM Tris at pH 8 containing 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1 mM DTT 
and complete protease inhibitors (Roche) and were lysed with a constant cell 
disruptor (Constant Systems LTD) at a pressure of 2.2 kbar in two passages.  To 
remove cell debris, the lysate was centrifuged at 15000 rpm for 30 minutes. The 
supernatant was then centrifuged for 42000 rpm for 1.5 hours in an ultracentrifuge. 
The supernatant containing the cytoplasmic fraction was discarded while the pelleted 
membranes were transferred to a homogenizer. The pellets were homogenized in 20 
mM Tris at pH 8 containing 20 mM NaCl and 20% glycerol. The total protein 
concentration was measured with a DC Protein Assay (BioRad) and the homogenized 
membranes were diluted to 6 mg/ml. The membranes were stored on -80°C.  
For LacY, all buffers contained HEPES buffer at pH 7.5 instead of Tris buffer at pH 
8. The ultracentrifugation step for PepTso was elongated to 2 hours due to less stable 
membrane pellet consistency.  
 
4.2.5 Purification of YdgR constructs  
 
4.2.5.1 Nickel affinity chromatography 
 
Membranes were thawed and diluted 1:1 with 20 mM Tris buffer at pH 8 containing 
580 mM NaCl, 2% DDM (Anatrace; final concentration 1%), 10 mM Alanlyl-alanine 
(Bachem; final concentration 5 mM) and 1 mM DTT (final concentration 0.5 mM).  
The membranes were incubated at 4°C for 1 hour on a rotator. To separate detergent- 
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solubilized protein from remaining membranes an ultracentrifugation step of 1 hour at 
42000 rpm at 4°C was performed. The supernatant was diluted 1:1 with 20 mM Tris 
at pH 8 containing 300 mM NaCl, 10% glycerol, 30 mM imidazole and 5 mM Alanyl- 
alanine and loaded on a HisTrap FF 5 mL column (GE Healthcare) with a rate of 3 ml 
per minute. The column was washed with 20 mM Tris buffer at pH 8 containing 300 
mM NaCl, 10% glycerol, 5 mM alanyl-alanine, 0.025 mM DTT, 30 mM imidazole 
and 0.03% DDM.  Bound protein was washed with 20 mM Tris buffer at pH 8 
containing 300 mM NaCl, 10% glycerol, 5 mM alanyl-alanine, 0.025 mM DTT, 
0.015% DDM and 65 mM imidazole and eluted with 20 mM Tris buffer at pH 8 
containing 300 mM NaCl, 10% glycerol, 5 mM alanyl-alanine, 0.025 mM DTT, 
0.015% DDM and 155 mM imidazole. The elution fractions were concentrated 
(Vivaspin 100 kDa molecular weight cut-off) and exchanged to 20 mM Tris buffer at 
pH 8 containing 150 mM NaCl, 10% glycerol, and 0.015% DDM.  
 
4.2.5.2  Size exclusion 
 
For crystallization trials, an additional purification step was performed. The elution 
fractions of Nickel affinity chromatography were diluted 1:1 with size exclusion 
buffer (20 mM Tris at pH 8 containing 150 mM NaCl, 5 mM Alanyl-alanine and 
0.015% DDM) to lower the content of imidazole before concentrating with Vivaspin 
100kDa. Otherwise an increased tendency for precipitation was observed. The 
fractions were concentrated to 5 ml and loaded on a Hi Load Superdex 200 16/60 
column (GE Healthcare) pre-equilibrated with size exclusion buffer. Fractions 
containing the target protein were concentrated to ∼3.5mg/ml with Vivaspin 100kDa 
and aliquots were stored at -80°C.  
 
4.2.6 Purification of PepTso  
 
Membranes of cells containing over-expressed PepTso were treated as described above 
for YdgR but instead of loading them on a His Trap FF 5ml column, 1ml Ni-NTA 
Superflow (Quiagen) per 10 ml membranes was added and the sample was rotated 
overnight at 4°C. The sample was then transferred into a gravity flow Econo-Pac 
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column (BioRad) and the resin was washed with 20 column volumes of 20m M Tris 
buffer at pH 8 containing 300 mM NaCl, 10% glycerol, 0.03% DDM and 30 mM 
imidazole. PepTso was eluted with 20 mM Tris at pH 8 containing 300 mM NaCl, 
10% glycerol, 0.03% DDM and 250 mM imidazole. The fractions containing Peptso 
were concentrated to 500 ul with Vivaspin 100 kDa and loaded onto a Superdex 200 
10/300 GL column (GE Healthcare) pre-equlibrated with 20 mM Tris at pH 8 
containing 150 mM NaCl and 0.02% DDM. The peak at an elution volume of ∼13 ml 
was concentrated and aliquots were stored at -80°C.  
 
4.2.7 Purification of LacY and C154G 
 
Native Lac Y and the mutant C154G were purified as described above for PepTso 
except that all buffers included HEPES buffer at pH 7.5 instead of Tris buffer at pH 8. 
Additionally a second washing step was included in the purification protocol 
containing the same components as the standard washing step, but the imidazole 
concentration was increased from 30 mM to 50 mM. 
 
4.3 Protein analysis and characterization  
 
4.3.1 Measurement of protein concentration 
 
Protein concentration was determined by measuring absorbance at 280 nm with a 
NanoDrop Spectrophotometer (PeqLab).  
 
4.3.2 SDS- polyacrylamide gel electrophoresis (SDS- PAGE) 
 
Proteins were submitted to SDS-PAGE to investigate protein size and purity. The gel 
consists of an upper stacking and a lower separating layer. For standard procedures 
12% SDS-PAGE gels were prepared (Table 4.5).  
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Table 4.5: Recipe for SDS-polyacrylamide gels 
 
 Components   Seperating gel (12%)           Stacking gel 
  
 1M Tris pH=8.8  12.5ml    - 
 1M Tris pH=6.8  -    1.25ml 
 30% Acrylamide mix  20ml    1.7ml 
 10% SDS   0.5ml    100ul 
 10% ammonium persulfate 0.5ml    100ul 
 TEMED   20ul    10ul 
 H2O    16.5ml    6.8ml 
 
 
To estimate protein size, PageRuler Unstained or Prestained Protein Ladder 
(Fermentas) was loaded next to the protein samples. The self-made SDS-PAGE gels 
were run at 25 mA per gel for ∼1 hour. 
Also commercial SDS-PAGE gels (NuPage, Invitrogen) including suitable 
commercial running buffer were used. Depending on the purpose electrophoresis was 
performed on 12% or 4-12% gradient gels. These gels were run at 160 Volt for ∼1.5 
hours. Afterwards proteins were detected with Page BlueProtein Staining Solution 
(Fermentas). The procedure was performed as instructed by the manufacturer.  
 
4.3.3 Silver staining 
 
Silver staining was used to detect proteins or peptides on SDS-PAGE gels in the 
nanogram range. All steps were performed in glass containers. This staining 
procedure can be used for self-made or commercial SDS-PAGE gels. 
The gels were loaded and run as described above. Then the gel was incubated for 5 
minutes in solution 1. The gel was quickly rinsed and then put into distilled water for 
5 minutes. After it was washed again with distilled water, it was incubated for 5 
minutes in solution 2 followed by 1 minute in solution 3. Again the gel was quickly 
rinsed with distilled water several times and put into solution 4 for 8 minutes. The gel 
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was rinsed with distilled water again several times and solution 5 was added. After the 
appearance of protein bands the reaction is stopped with 1% (v/v) glacial acetic acid.  
 
Table 4.6: Protocol for silver staining 
 
  Solution   Components     
  
Solution 1 60 ml 50% (v/v) acetone, 1.5 ml 50% (v/v) TCA 
in water, 25 ul formaldehyde solution 
(purchased as 37% solution) 
Solution 2   50% (v/v) acetone in water 
Solution 3 100 ul 10% (w/v) Sodium Thiosulfate 
pentahydrate in 60 ml water 
Solution 4 0.8 ml 20% (w/v) silver nitrate, 0.6 ml 
formaldehyde solution (purchased as 37% 
solution) in 60 ml water 
Solution 5 1.2g Na2-carbonate, 25 ul formaldehyde solution 
(purchased at 37% solution), 25 ul sodium 
thiosulfate in 60 ml water 
  
 
4.3.4 Western Blot analysis 
 
Self-made or commercial SDS-PAGE gels were run as described above with 
PageRuler Prestained Protein Ladder as a protein size marker. The protein bands 
were transferred electrically to a PVDF membrane (Millipore) at 400mA for 1.5 hours 
at 4° C. Afterwards the membrane was blocked in 20 ml blocking buffer containing 
TBS-T with 5% milk powder for 20 minutes. Then the membrane was incubated in 
TBS-T, 5% milk powder and penta-His HRP-conjugated antibody (Qiagen) at a 
dilution of 1:10000 for 2 hours at room temperature or overnight at 4°C. The 
membrane was washed 5 times for 7 minutes in TBS-T. The luminescence of 
antibody-bound protein bands was detected with the SuperSignal West Pico 
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Chemiluminescent Substrate (Thermo Scientific) on a chemiluminescent film 
(Hyperfilm ECL, GE Healthcare).  
 
Table 4.7: Buffers for SDS-PAGE and Western Blot 
 
 Buffer    Composition   
  
1× SDS running buffer  25 mM Tris/HCl pH 8.3, 200 mM glycine, 0.1% 
(w/v) SDS 
2× SDS loading buffer 125 mM Tris pH 6.8, 30% glycerol, 2% SDS, 6 
M urea, 1 M β-mercaptoethanol, 0.2% 
bromophenol blue 
10× Tansfer Buffer  250 mM Tris, 1.92 M glycine 
Transfer Buffer 200 mL 10× TB, 200 mL methanol, 1600 mL 
dH2O 
 10× TBS   200 mM Tris-HCl pH 7.5, 1.5 M NaCl  
TBST 100 mL 10×TBS, 1 mL Tween 20 in 1000 mL 
dH2O 
 
 
4.3.5 Stargazer thermostability assay  
 
Purified native and mutant YdgR proteins were diluted to 0.1 mg/mL and 0.2 mg/mL 
in 50 mL of 20 mM HEPES buffer at pH 7.5 containing 150 mM NaCl, 10% glycerol, 
and 0.03% DDM in a black 384-well plate with a clear buttom (Nunc).  The plate was 
centrifuged for 2 minutes at 400 rpm and 50 mL of mineral oil were added to each 
well and the plate was centrifuged again.  The thermal aggregation (Tagg) curves for 
each protein were determined with the Stargazer instrument (Harbinger Biotech).  
Regression analysis of the curves to determine the Tagg’s was performed with the 
program Bioactive (Harbinger Biotech). For testing different buffers for 
crystallization purposes, native YdgR was diluted to 0.1 mg/ml in a buffer screen. 
Additives were used in a ratio of 1:10. 
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4.3.6 Dynamic light scattering (DLS) 
 
A DynaPro801 molecular sizing instrument (Protein Solutions Inc.) was used for DLS 
measurements. The samples were centrifuged for 10 minutes at 10000g to remove any 
contamination. Buffer alone was analyzed as a reference to rule out contamination of 
the cuvette. 15 ul samples were measured in a quartz cuvette at 19° C. Data Analysis 
was performed with Dynamics V6 software (Protein Solutions Inc.) 
 
4.3.7 Analytical size exclusion YdgR, LacY and PepTso 
 
Purified native and mutant YdgR proteins were diluted to a concentration of 1 mg/ml. 
70 mL of protein were incubated for 5 minutes at either 4° C or 50°C. The samples 
were centrifuged for 10 minutes at 10,000g before loading 50 mL onto a Superdex 
200 PC 2.1 column (GE Healthcare) equilibrated in 20 mM Tris buffer at pH 8 
containing 150 mM NaCl, 10% glycerol, and 0.03%DDM. For LacY and C154G also 
50ug were loaded. For PepTso only 25ug were loaded.  
 
4.3.8 CPM fluorescence-based thermostability assay  
 
Purified native and mutant YdgR proteins were diluted to a concentration of 3 mg/mL 
in 20 mM Tris buffer at pH 7.5 containing 100 mM NaCl and 0.03% DDM.  1.5 mL 
protein were added to 150 mL of the same buffer containing different detergents, each 
at a concentration 3-fold above its CMC.  CPM was dissolved in DMSO at a 
concentration of 4 mg/mL. The dye was diluted 1:100 in 20 mM Tris buffer at pH 7.5 
containing 100 mM NaCl and 0.03% DDM, and 3 mL of the CPM dilution were 
added to each protein sample.  The fluorescence of triplicate values of each sample 
(excitation 387 nm; emission 463 nm) was measured every 5 minutes over 150 
minutes at a temperature of 40° C in a black 96-well plate using a Synergy 2 
fluorescence plate reader (Biotek). The fraction of unfolded protein at each time point 
was determined as in [39]. 
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4.3.9 Lysine acetylation 
 
Sulfo-NHS Acetate (Thermo Scientific) was dissolved at a concentration of 2.6 
mg/ml (10 mM) in purified, distilled water. Native YdgR, S166G, N196K and 
S166G/N196K were diluted to 0.1 mg/ml in 100 mM HEPES buffer at pH 7.5 
containing 150 mM NaCl and 0.015% DDM. 3.8 ul crosslinker were added per 100 ul 
sample volume. The reaction was incubated for 1 hour at room temperature and 
stopped by removing the cross-linker by desalting. Proteolytic digestion and mass 
spectrometry analysis were performed by the in-house mass spectrometry facility. 
 
4.4 In vivo functional assays 
4.4.1 Membrane Localization 
 
50-100mL of E. coli C43(DE3) cells were grown according to the standard protocol. 
The cells were harvested at 4000 rpm and resuspended in 1 ml 20 mM Tris at pH 8 
containing 150 mM NaCl, 10% glycerol, complete protease inhibitors (Roche), 1 
mg/ml lysozyme and 25 units/ml Benzonase nuclease per measured OD600. The cells 
were incubated on ice for 30 minutes. To improve efficiency of lysis, ∼1ml of 0.1 mm 
glass beads was added per ml lysate and were placed in a cell disruptor for 3 minutes 
at 4° C. Cell debris was removed by centrifugation at 13000 rpm at 4°C for 30 
minutes. The supernatant was removed gently by pipetting with gel loading tips and 
membranes were pelleted in a table-top ultracentrifuge at 42000 rpm for 1.5 hours at 
4°C. The supernatant was discarded and the membrane pellet was washed twice with 
200 ul buffer 20mM Tris at pH 8 containing 150 mM NaCl and 10% glycerol. Then 
the membranes were resuspended in 100 ul 20 mM Tris buffer at pH 8 containing 20 
mM NaCl using a small plastic homogenizer. The total protein concentration was 
measured with the DC Protein Assay (Bio Rad) and the homogenized membranes 
were diluted to equal concentrations.  
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4.4.2 Alafosfalin growth assay  
 
The mutants were transformed into E. coli BL21(DE3) and individual colonies were 
inoculated in 1ml LB- cultures in 2 ml 96-well plates and grown overnight at 37°C 
with shaking at 190 rpm. These pre-cultures were transferred to transparent 96-well 
plates and the cells were grown under two conditions, one containing 200 µL of 
Luria-Bertani (LB) medium plus the antibiotic ampicillin, and one additionally 
containing 200 µg/mL of the antibiotic alafosfalin (Sigma-Aldrich) at 37°C at 190 
rpm. The cells were induced with 0.01 mM IPTG at an OD600 of 0.2-0.3. The OD600 
was measured at different time points with a Synergy 2 fluorescence plate reader 
(Biotek).  
 
4.4.3 Uptake of b-Ala-Lys(AMCA) 
 
Constructs were transformed into E. Coli BL21(DE3) cells as described above and 
liquid pre-cultures in LB medium containing 2% glucose and 100 µg/ml ampicillin 
were set up and grown overnight at 37°C with shaking at 220 rpm. 250 µl of the pre-
culture were spun down and resuspended in fresh medium for inoculation in 25 ml 
liquid cultures in 100 ml baffled flasks. The cells were grown to an OD600 of 0.6 and 
were then induced with 0.1 mM IPTG. Expression was carried on for 1 hour. The 
cultures were put on ice and the OD600 was measured again. A concentration of 
3.25×109 cells/ml was intended for the assay. (An OD600 of 1 corresponds to 
approximately 8×108 cells/ml.) The adequate volume of culture was spun down and 
resuspended in 1 ml of Kreb’s buffer. Triplicate samples of 40 ul of cells were added 
to 60 uL of buffer, substrate solution or competitor solution in a 96-well V-bottom 
plate. The plate was covered with an Airpore sheet (Qiagen) and put in the shaker at 
37°C for 15 minutes at 180 rpm. The cultures were pelleted and washed 3 times with 
Krebs buffer. Then the cells were resuspended in 100 ul Krebs buffer and were 
transferred to a 96-well black-walled plate with a clear bottom. The fluorescence 
signal and OD600 were measured with a Synergy 2 fluorescence plate reader (Biotek) 
with an excitation filter of 360/40 and an emission filter of 460/40.  
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Table 4.8: Solutions for b-Ala-Lys(AMCA) uptake assay 
 
 Solution   Components     
  
Kreb’s buffer 25 mM Tris buffer at pH 7.5, 140 mM NaCl, 5.4 
mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 5 
mM glucose 
β-Ala-Lys-(AMCA) stock 2.5 mM stock in DMSO freshly dissolved prior 
to the assay  
Substrate solution 10ul of 2.5 mM β-Ala-Lys-(AMCA) stock in 
50ul Kreb’s buffer 
Competitor solution 10ul of 2.5 mM β-Ala-Lys-(AMCA) stock with 
50 ul of 20 mM competitor dissolved in Kreb’s 
buffer 
  
 
4.5  Generation of conformationally specific Fab fragments 
 
4.5.1 Purification of tag-free and N- and C-terminally truncated YdgR 
 
N-terminal His10 YdgR 6-498 with a TEV protease cleavage site was purified via Ni-
NTA affinity chromatography as described above and the His-tag was cleaved off by 
incubation with TEV protease overnight at 4° C. The His-tag and TEV protease were 
removed by re-binding to Ni-NTA agarose in batch. Then gel filtration 
chromatography using a HiLoad Superdex 200 16/60 column (GE Healthcare) was 
performed as described above. 
 
4.5.2 Reconstitution of YdgR into proteoliposomes 
 
Powdered E. coli polar lipid extract (AVANTI POLAR LIPIDS Inc.) was diluted in 
chloroform at a concentration of 20 mg/ml. 500 ul were dried in a faint nitrogen gas 
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stream and resuspended in 20 mM Tris at pH 7.5 containing 150 mM NaCl. 100 ul of 
10% DDM were added and the lipid-detergent mix was sonicated in a water bath for 
30 min. 400 ul of YdgR 6-498 as diluted in 20 mM Tris buffer at pH 7.5 containing 
150mM NaCl, 5% Glycerol, 0.1 mM DDT and 0.06% DDM at a concentration of 
0.25 mg/ml and was added to the lipids followed by incubation for 10 min on ice. 
500mg Bio-Beads (Biorad) washed in 20 mM Tris at pH 7.5 containing 150mM NaCl 
were added and the sample was rotated at 4° C overnight. The beads were removed in 
the morning and 200 mg fresh washed Bio-Beads were added. After incubation for 4 
hours the sample was centrifuged for 90 minutes at 42000 rpm. The pellet was 
resuspended in 20 mM Tris buffer at pH 7.5 containing 150 mM NaCl. To remove 
unfolded and/or unincorporated protein, a final spin step at 13000 rpm for 2 minutes 
was performed. 
 
4.5.3 Monoclonal antibody generation  
 
Proteoliposomes containing YdgR were used for serial immunization of three mice by 
the MFPL monoclonal antibody facility.  The proteoliposomes were freshly prepared 
before each injection. Supernatants of hybridoma cell lines 5E8-D6 and 5E3-F10 
were supplied by the MFPL antibody facility. Both antibodies are Western blot 
negative and ELISA positive. 
 
4.5.4 Large-scale production of monoclonal antibodies 
 
The hybridoma cells were grown in X63 Medium containing per 500 ml 435 ml 
DMEM (Dulbecco’s Modified Eagle’s Medium- high glucose; Sigma), 50 ml Fetal 
calf serum (Sigma), 5 ml Penicillin and Streptomycin (Sigma), 5 ml Glutamine 
(Sigma) and 5 ml Na-Pyruvate (Sigma). When the cells reached high density, the cells 
were gently removed from the bottom of the culture dish by pipetting. The cells were 
centrifuged at 800g for 4 minutes, were gently resuspended in new medium and were 
split into new culture dishes. For inoculation of the FiberCellHollow Fiber 
Cartridge (Fiber Cell Systems Inc.), 1-2×108 cell are necessary which corresponds to 
approximately 10 culture dishes (15cm). The Fiber cell bioreactor was washed for 2 
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days with 1× PBS and for 2 days with X63 Medium after which the cells were 
injected into the chamber. After two days the glucose consumption was measured 
with a Lactate Kit (Reagent 10×10mL; Trinity Biotech).  Lactate values >0.6 indicate 
that the medium should be changed and values >0.8 indicate that antibodies could be 
harvested. Subsequently the medium was changed and antibodies were harvested once 
per day. Dead hybridoma cells were spun down at 1200g and 0.02% sodium azide 
was added to the supernatant containing the antibody. The supernatant was stored at 
4°C.  
 
4.5.5 ELISA (Enzyme-linked immunosorbent assay) 
 
The 96-well Nickel-coated plates (Pierce) were coated overnight at 4°C with antigen 
coating solution. The wells were washed twice with washing buffer. Since the plates 
are pre-blocked, a blocking step is not necessary. The next day, the wells were 
incubated with 50 ul Antisera solution per well for 1 hour at room temperature. Then 
the wells were washed three times with 50 ul washing buffer containing 50 mM 
imidazole to reduce the background of Nickel-binding proteins. Additionally the 
plates were washed twice with 50 ul washing buffer. The plates were incubated with 
50 ul antibody solution for 1 hour at room temperature or overnight at 4°C. Then the 
wells were washed three times with washing buffer. 50 ul substrate solution was 
added. Positive wells develop a blue color that changes to yellow when the reaction is 
stopped with 50 ul 1N H2SO4. The color reaction was quantified by measuring the 
absorption at 450 nm with a Synergy 2 fluorescence plate reader (Biotek). 
 
Table 4.9: Solutions for ELISA 
 
 Solution   Components     
  
Washing buffer 1× PBS, 0.03% DDM, 0.1% BSA 
Antigen coating solution  Washing buffer with TEV-cleaved N-terminally 
his-tagged YdgR 6-498 at a concentration of 5-
10 ug/ml 
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Antisera solution 1:1000 dilution of cell supernatant in washing 
buffer 
Antibody solution 1:10000 dilution of HRP conjugated rabbit anti-
mouse antibody in washing buffer  
TMB stock solution 1mg of 3’,5’,5’,5’-tetramethylbenzidine (Sigma) 
in 300 ul DMSO (stored at -20°C) 
Substrate solution  100 ul TMB stock in 10 ml 100 mM Na-acetate 
pH 6 containing 0.01% H2O2 
  
 
4.5.6 Monoclonar antibody (mAb) purification   
 
Supernatant (containing 0.1- 0.4 mg/ml mAb) was concentrated 20 times in a 
VIVASPIN column with a 100k molecular weight cut-off and diluted 1:5 with 20 mM 
sodium phosphate buffer at pH 7. The pH was adjusted to ~6.5. After loading onto a 1 
mL Hi Trap Protein G column (GE Healthcare), the column was washed with 10 
column volumes 20 mM sodium phosphate at pH 7. The mAb was eluted with 100 
mM Glycine at pH 2.7. Tubes were pre-filled with 100 ul 1M Tris buffer at pH 8.5 
per 1 ml eluate for immediate neutralization.  
 
4.5.7 Analytical size exclusion of mAb-YdgR complexes  
 
30 ug mAb were incubated with 30 ug native or mutant YdgR for 90 min at 4°C and 
then loaded onto a Superose 6 PC 3.2/30 column (GE Healthcare). The running buffer 
contained 20 mM Tris buffer at pH 8, 150 mM NaCl, 10% glycerol and 0.015% 
DDM. 
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4.6 Protein crystallization 
 
4.6.1 Crystallization in detergent 
 
Purified native and mutant YdgR proteins were concentrated to ~3.5 mg/mL and 
crystallization trials were set using the sitting drop vapor diffusion method using the 
commercial screens Mem Gold, MemStart and MemSys (Molecular Dimensions). 
Intial screening was carried out with a Mosquito robot (TTP lab tech) in ratios of 100 
mL protein: 100 mL reservoir and 200 mL protein: 100 mL reservoir. Optimization  
was performed in 96 well or 24 well screens in a grid screen manner pipetted with a 
Liquid handling Alchemist II  robot. 
For co-crystallization with monoclonal Fab fragments, the purified Fab was mixed 
with purified YdgR in a 1:2 and loaded onto a Superdex 200 10/300 GL or a Hi Load 
Superdex 200 16/60 column (GE Healthcare). The eluted complex was concentrated 
to 6.5mg/ml and used for crystal trials in commercial crystal screens. 
 
4.6.2 Crystallization after relipidization 
 
E. coli Polar Lipid Extract (Avanti, Polar Lipids Inc.) in Chloroform was transferred 
to small glass vials in amounts of 0, 0.25 and 0.5 mg. The chloroform was removed 
under a faint nitrogen stream. Three tubes of each concentration were prepared. 100 ul 
of the target protein at a concentration of 5-10 mg/ml were added to each tube. 
Subsequently, different detergent concentrations (0, 1.5 and 3 mg) were added per 
lipid concentration from a 100 mg/ml stock, resulting in nine samples in total. The 
samples were incubated with stirring at 4°C for 10-20 hours. The insoluble material 
was removed by ultracentrifugation at 42000 rpm for 10 minutes. The supernatant 
was then used for crystallization trials.  
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4.6.3 X-ray Diffraction 
 
Crystals were frozen in mother liquor since all described conditions were 
cryoprotectants themselves. The crystals were shipped to the European Synchrotron 
Radiation Facility (ESRF) Grenoble and tested. 
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5 Results 
 
5.1 Crystallization of native YdgR 
 
5.1.1 Optimization of native YdgR purification 
 
Initially, purification of YdgR was performed via batch Nickel affinity 
chromatography using an econo-column (as described Materials and Methods for 
PepTso) followed by size exclusion chromatography. YdgR does not run at its actual 
molecular weight of 55 kDa on SDS-PAGE, which commonly occurs with integral 
membrane proteins and is most likely due to a very high capacity for SDS binding 
[45].The YdgR monomer band can be detected at a size of ∼38 kDa and, as is also 
common for membrane proteins, a dimer band (∼76 kDa) is visible in SDS-PAGE, 
which is most likely an artifact due to incomplete or aberrant denaturation with SDS, 
as no biological relevance has been shown for a dimer [61]. After batch Nickel 
affinity chromatography, the eluted fractions contained YdgR and impurities of 
various sizes (Figure 5.1 a). Even after size exclusion, impurities with a molecular 
weight of ∼50kDa, ∼30kDa and ∼18kDa were detected on SDS-PAGE gels in a peak 
overlapping with the main fraction of YdgR. The peak containing the impurity and 
the pure YdgR peak could not be separated completely via size exclusion (Figure 5.1).  
 
The 50 kDa band was identified by mass spectrometry as the subunit HslU belonging 
to the HslU/HslV complex. This complex contains the protease HslV and the ATPase 
HslU, a chaperone of the Clp/Hsp100 family. Most probably this complex binds and 
processes YdgR in vitro and therefore co-elutes with YdgR. An increase in the 
∼30kDa band correlates with an increased amount of the HslU/HslV complex and can 
most probably be regarded as partially digested YdgR.  
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Figure 5.1: a. SDS-PAGE after batch Nickel affinity chromatography; b. Chromatogram and SDS-
PAGE of size exclusion chromatography on Superdex 200 16/60 
 
Since size exclusion was not sufficient to separate YdgR from these impurities, the 
Nickel affinity chromatography step was optimized. On-column binding and Stepwise 
elution with imidazole from a His Trap FF 5ml column improved purity dramatically 
as can be easily observed when fractions of batch purification and on-column 
purification are compared by SDS-PAGE (Figure 5.1 a and Figure 5.2 a). In the batch 
purification all fractions contain the HslU/HslV complex and partial degradation of 
YdgR can be observed. These impurities are removed on the His Trap FF 5ml column 
by a washing step with buffer containing 65 mM imidazole. Some YdgR was also 
removed in this step, but in the next step with buffer containing 155 mM imidazole 
pure YdgR without traces of the HslU/HslV complex is eluted (Figure 5.2 a). The 
profile of the subsequent gel filtration shows a sharp peak and fractions analysed via 
SDS-PAGE are free of HslU/HslV complex (Figure 5.2 b).  Therefore on-column 
Nickel affinity chromatography via FPLC and subsequent size exclusion became the 
standard procedure for purification. 
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Figure 5.2: a. Chromatogram and SDS-PAGE of Nickel affinity chromatography on His Trap FF 5ml 
column; b. Chromatogram and SDS-PAGE of gel filtration on Superdex 200 16/60 
 
5.1.2 Optimization of Protein Stability and Monodispersity 
 
Initial crystal trials with full length C-term His6 (uncleavable) native YdgR using 
commercial 96-well screens were set up. Unfortunately only detergent crystals or 
phase separation was observed (Figure 5.3).  
 
 
Figure 5.3: Result of initial crystal trials showing detergent crystals in different conditions 
 
Since buffer conditions can affect protein stability, homogeneity, monodispersity and 
therefore crystallizability [13; 38] the Stargazer assay was used to test thermostability 
of YdgR in different buffers. The Stargazer is an instrument that measures static light 
scattering while the target protein is heated up continuously in a 384-well plate. An 
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increasing static light scattering signal indicates the thermally induced unfolding 
process of the target protein. The typical experimental outcome is a sigmoidal curve, 
whose point of inversion is identical to the aggregation temperature of the protein. 
Stabilizing buffers and additives should inhibit the thermally induced unfolding 
process and increase the aggregation temperature. Figure 5.4  shows two typical 
thermal unfolding curves of YdgR.  
 
Figure 5.4: Comparison of thermal unfolding curves of YdgR in two different buffers. YdgR shows 
increased thermostability in the buffer indicated in orange.  
 
To optimize buffer conditions for YdgR, a buffer screen was established that contains 
24 different buffers in a pH range of 3-10 (Table 5.1). These buffers are combined 
with either no salt, 100 mM NaCl, 300 mM NaCl or 100 mM (NH4)2SO4, resulting in 
a 96-condition screen. Since Tris at pH 8 is used as a standard buffer for purification, 
the results were compared to the aggregation temperature (Tagg) of native YdgR in 
this buffer. YdgR has an approximate Tagg of 55°C in Tris pH 8 while its Tagg is 
increased by ∼3°C in buffers with a pH between 4-5.5 independent of the salt or its 
concentration while the other buffers do not contribute to protein stabilization. 
 
Table 5.1 : Tested buffers 
 
 Buffers (final conc. 50 mM) pH  Tagg   Solubility Kit  
  
 Glycine   3  - 
 Na-citrate  4  +3°C  Precipitate 
 Na- acetate  4.5  +3°C  Precipitate 
 Na- phosphate   5  +3°C  Precipitate 
 Na-citrate  5.5  +3°C  NO Precipitate 
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 Na-phosphate  5.5  +3°C  Precipitate 
 MES    5.8  - 
 Na/K-phosphate  6  - 
 Bis-Tris   6  - 
 MES    6.2  - 
 Na-phosphate  6.5  - 
 Sodium cacodylate  6.5  - 
 MOPS   7  - 
 Na/K- phosphate 7  - 
 HEPES   7.5  - 
 Tris   7.5  - 
 Imidazole  8  - 
 Tris (Standard)  8  ∼55°C  
 Bicine    8  - 
 Tris   8.5  - 
 Bicine    8.5  - 
 CHES   9  - 
 CHES   9.5  - 
 CAPS   10  - 
 
 
The five potential stabilizing buffers were also tested using the JBS Solubility Kit 
(Jena Bioscience). This kit is normally used as a pre-screen for crystallization buffers. 
The buffer is mixed with the target protein in a hanging drop over a buffer reservoir. 
Depending on the protein’s stability in the buffer, aggregation will be visible after 24 
hours at room temperature. Only for Na-citrate pH 5.5 was no precipitate visible (as 
indicated in Table 5.1). Therefore this buffer seems to be suitable for crystallization. 
To determine the stabilizing effect of different additives, a commercial 96-well 
Additive Screen (Hampton Research) was used. The additives were tested in the 
Stargazer in combination with 50 mM Na-citrate buffer pH 5.5 as described in 
Materials and Methods. Figure 5.5 a shows the aggregation temperatures Tagg of a 
selection of additives. The additives in blue show a stabilizing effect while some 
additives such as Copper chloride (red) destabilize the target protein. Most of the 
additives show no effect (black). Out of 96 additives 4 seemed to have a repeatedly 
observed stabilizing effect. Glycerol, CaCl2 and Aminohexanoic acid increased the 
Tagg of the target protein by approximately 2-3° C while NDSB-256 raised the values 
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by 5-6°C. Since this is a quite strong effect compared with the other stabilizing 
additives, which should be confirmed unambiguously, the monodispersity of the 
target protein in a buffer containing NDSB-256 was tested via Dynamic Light 
scattering. Since the sample monodispersity increased from 16% to 20% when 
NDSB-256 was added to protein in a 100 mM Citrate buffer pH=5.5, this component 
was identified as a false positive (Figure 5.5 b). As a control the dipeptide Alanyl- 
alanine was added to 100 mM Citrate buffer pH 5.5. This dipeptide is a substrate of 
the target transporter YdgR and should therefore have a stabilizing effect [44; 50; 51]. 
A decrease of polydispersity from 18% in buffer alone to 12% in buffer containing 
the dipeptide could be detected (Figure 5.5 b). Therefore the crystallization buffer 
used for future crystal trials contained 20 mM Na-citrate pH 5.5, 40 mM CaCl2, 10% 
glycerol, 15% Aminohexanoic acid, 25mM Alanyl-alanine and 0.15% DDM.  
 
 
Figure 5.5: a. Aggregation temperatures of YdgR in buffers containing different additives  (stabilizing 
addititives in blue; destabilizing addititives in red; additives with no effect in black); b. Results of DLS 
in buffers with NDSB-256 or Alanyl-alanine 
 
5.1.3 Crystallization trials with native YdgR 
 
Purified native YdgR was exchanged into the new optimized crystallization buffer 
and crystal trials were performed in 96-well plates as described in Materials and 
Methods. The focus of screening was put on commercial crystal screens designed for 
membrane proteins based on crystal hits of other membrane proteins, namely 
MemStart/MemSys and MemGold (Molecular Dimensions).  
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After one week small needles could be observed in condition 2.26 of the MemGold 
screen containing 50 mM glycine and 55% PEG 400. The needles were quite small 
and could not be fished for analysis and therefore the first hit had to be repeated and 
optimized. The optimization procedure was performed in 24-well plates in sitting- 
drop format. PEG 400 was varied between 40 and 60%. Different buffers at pH=9 
were tested but only the pH but not the buffer identity seemed to be important, 
therefore 100 mM Tris at pH 9 was used for further trials. Since the Stargazer 
experiments suggested the positive influence of CaCl2 on target protein stability, also 
CaCl2 (0-40 mM) and NaCl (0-150 mM) were tested as additives in crystallization. 
Both salts seemed to have a positive effect on crystallizability and showers of needles 
and larger needles could be observed. The crystals could be optimized to rod-like 
structures, due to the increase or decrease of PEG 400 and the addition of CaCl2 or 
NaCl respectively. The largest crystals were grown in 100 mM Tris pH 8 containing 
58% PEG 400 and 12 mM CaCl2 (Figure 5.6 a). 
 
 
 
Figure 5.6: a. Optimized crystals; b. Crystals analyzed by SDS-PAGE followed by Silver staining; c. 
Crystal in a loop at ESRF Grenoble and the resulting diffraction pattern 
 
Some crystals were washed in mother liquor and loaded onto an SDS gel. Since a 
protein band at the size corresponding to YdgR was visible after silver staining, the 
crystals consisted of the target protein (Figure 5.6 b). The largest crystals were fished 
and frozen. No cryo-protectant was necessary because the crystallization condition 
contained a high percentage of PEG 400. For diffraction analysis, the crystals were 
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sent to the European Synchrotron Radiation Facility (ESRF) in Grenoble. 
Unfortunately resolution was limited to 10 Å (Figure 5.6 c). Since a higher resolution 
is necessary for structure determination, no structural information could be gained, 
and there were too few reflections to index the images in order to determine the space 
group and size of the unit cell. Optimization of crystals was continued but no crystals 
could be observed in the new screens. Additionally crystals could not be reproduced 
in the known crystallization condition. Several screens were set up with different 
batches of protein but no crystals could be grown. Since delipidization due to 
purification conditions can affect the crystallization of membrane proteins, 
relipidization was performed as described in Materials and Methods, but did not result 
in any crystals. Also screening with commercial screens was repeated and expanded 
but did not give any hits.  
Therefore new strategies were necessary to increase the probability of growing well-
diffracting crystals that could be used for structure determination.  
 
5.2 Co- crystallization with monoclonal antibodies  
 
5.2.1 Generation of hybridoma cell lines 
  
For antibody generation a truncated YdgR construct with a cleavable N- terminal his- 
tag (N-terminal His10 YdgR TEV site 6-498) was used to eliminate the possibility of 
an immune response to the His 10-tag or to the flexible N and C termini of the 
protein. As described above in Materials and Methods purified protein was 
reconstituted into proteoliposomes that were used for immunization of three mice. 
Additionally three mice were injected directly with purified protein solubilized in 
detergent alone. To check if immunization resulted in an immune response, diluted 
bleeds of the mice (1:1000) were analyzed by ELISA and Western Blot (Figure 5.7). 
Pre-immunization bleeds show low immunological reactivity against YdgR while 
post-immunization bleed 1 and 2 show a clear response to YdgR in both methods.  
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Figure 5.7: ELISA (a) and Western blot (b) analysis of pre-bleed, first, and second bleed of immunized 
mice 
 
Immunization, spleenectomy of mouse 3 immunized with proteoliposomes, fusion 
with myeloma cells and subsequent production of hybridoma cells were performed by 
the MFPL antibody facility. As mentioned previously, monoclonal antibodies suitable 
for co-crystallization with a membrane protein should only detect correctly folded 
proteins and therefore should not bind to unfolded protein or protein aggregate. 
Therefore they should be Western blot negative but ELISA positive. The supernatants 
of hybridoma clone mixtures were tested for their specificity for a conformational 
intact epitope via ELISA.  Out of approximately 500 clone mixtures 23 wells showed 
a clear positive signal as compared to background (> 2 fold above background signal 
in other wells). These clone mixtures were tested by Western Blot for their ability to 
interact with unfolded protein (Figure 5.8 a). Nine showed a clear positive signal for 
interaction with unfolded YdgR. These mixtures of clones could be ruled out for 
further processing. There was also a slight signal visible for the other clone mixtures, 
however, since the clones were not diluted to single clones yet, this was expected.  
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Figure 5.8: a. Western blot analysis of ELISA positive hybridoma mixtures (exposure time of 5 
minutes); b. Western blot of single clones derived from hybridoma mixtures 5E8 and 5E3 (Exposure 
time of 5 minutes); c. ELISA of single clones derived from hybridoma mixtures 5E8 and 5E3 
 
Mixtures 5E3 (lane 4) and 5E8 (lane 5) were selected and diluted to single clones. 
Nearly all of them were clearly Western blot negative (Figure 5.8 b) and ELISA 
positive (Figure 5.8 c) and two clones were selected. The cell lines 5E3-F10 and 5E8-
D6 were derived by the MFPL antibody facility. Therefore the whole procedure 
successfully generated two Western-negative and ELISA-positive hybridoma cell 
lines.  
5.2.2 Generation and purification of monoclonal antibodys (mAb’s)   
 
The hybridoma cell lines 5E3-F10 and 5E8-D6 were injected into two 
FiberCellHollow Fiber Cartridges (Fiber Cell Systems Inc.). The bioreactors were 
operated as described in Materials and Methods. The monoclonal antibodies were 
purified as described in Materials and Methods with a 1 mL Hi Trap Protein G 
column. Cell supernatants contained high amounts of bovine serum albumin (BSA). 
This is usually the main impurity present during the purification of mAb’s from cell 
supernatants. Therefore the supernatants were concentrated with VIVASPIN 
concentrators with a molecular weight cut-off of 100 kDa. Since BSA has a molecular 
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weight of 68 kDa, quite a lot of BSA could be removed this way, additionally binding 
of mAb to protein G is improved when sample volumes are low. Nevertheless the 
applied sample still contained high amounts of BSA that could be easily observed by 
SDS-PAGE (Figure 5.9 b). Nevertheless, binding to Protein G is highly specific and 
therefore very pure antibody could be eluted from the column via decrease in pH from 
7 to 2.7 (Figure 5.9 a). The results of a typical purification are shown on a reducing 
SDS gel. Under reducing conditions the disulfide bonds between the heavy chain and 
the light chain are broken and both run separately on the gel. For 5E3-F10 and 5E8-
D6 approximately 4-5 mg/harvest and 1-2 mg/harvest of antibody respectively could 
be purified from the cell supernatant.  
 
 
Figure 5.9: a. Typical purification profile from a 1ml Hi Trap Protein G column (loading peak in rose 
and elution peak in blue); b. Reducing SDS-PAGE of fractions of loading peak and elution peak 
 
5.2.3 Complex formation with native YdgR and mutants 
 
The immunization of the mice was performed with proteoliposomes derived from a 
truncated N-terminal his-tagged cleaved version of native YdgR. Therefore the 
interaction of other YdgR constructs and mutants with the two monoclonal antibodies 
was tested via analytical size exclusion on a Superose 6 column (GE Healthcare) 
before co-crystallization trials were set up.  
 
Due to the detergent micelle surrounding YdgR, YdgR and the monoclonal antibodies 
show quite similar elution profiles on a Superose 6 column with peak maxima at 1.67 
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ml and 1.64 ml respectively. In cases where YdgR and mAb interacted and formed a 
complex, the complex eluted at ≤1.5ml. (Figure 5.10 a). In the experimental set-up an 
excess of mAb was added. Therefore an additional peak for mAb could be observed 
even after complex formation. 
As expected, mAb 5E8-D6 formed an antigen-antibody complex with the N-terminal 
his-tagged cleavable version of native YdgR (Figure 5.10 b), independent of the 
removal of the His-tag with TEV (data not shown) while absolutely no interaction 
was visible with either the C-terminal His-tagged native construct or any mutant 
constructs (Figure 5.10 c-g). The mutants are described and characterized in detail in 
chapter 5.3. This antibody seems to be specific for native YdgR. Most probably the 
epitope is located in a loop that is not accessible in the mutants. Additionally the C-
terminal His-tag seems to block the epitope on YdgR and no interaction with 5E8-D6 
can be observed.  
 
 
Figure 5.10: Size exclusion profiles of different constructs with mAb 5E8-D6 on a Superose 6 column  
 
5E3-F10 was also tested with different constructs of native and mutant YdgR. 
Antibody-antigen interaction could be observed for all N-terminal and C-terminal 
His-tagged constructs (Figure 5.11 a-h). S166G, N196K as well as the double mutant 
were detected by the antibody, independent of His-tag location or removal (Figure 
5.11 d-h). This antibody seems to interact with a more general or more generally 
exposed epitope on YdgR and its related mutants.  
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Figure 5.11: Size exclusion profiles of different YdgR constructs with mAb 5E3-F10 on a Superose 6 
column 
 
5.2.4 Generation and purification of monoclonal Fab fragments 
 
For co-crystallization, the monoclonal antibodies had to be cleaved to generate 
monoclonal Fab (mFab) fragments. The monoclonal antibodies contain flexible 
regions beween the Fab and the Fc region that make crystallization of a full mAb 
quite difficult, while monoclonal Fab fragments are ordered and compact. Normally 
mAb are cut for this purpose with papain endoprotease. Both antibodies were 
classified as IgG1 antibodies by the MFPL antibody facility. This subtype is difficult 
to cut with papain but ficin endoprotease normally gives good results [4]. Therefore a 
Mouse IgG1 Fab and F(ab')2 Preparation Kit (ThermoScientific) based on ficin 
cleavage was used for both antibodies. The protocol was performed as described by 
the manufacturer, but the incubation times for the cleavage had to be optimized. 
Generally the mAb were cleaved for 4 hours. Longer cleavage times support further 
digestion of monoclonal Fab fragments even if the digest of mAb is not complete. 
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Due to the overdigestion, no interaction between the antigen and mFab fragments can 
be detected anymore.  
Fc fragments and undigested mAb were separated from monoclonal Fab fragments 
with a Protein A Spin column. In contrast to Protein G, Protein A does not interact 
with Fab fragments and they can be found in the flow through as shown in Figure 
5.12 using non-reducing SDS-PAGE. Since the disulfide bonds are intact, the Fab 
fragment runs at its actual size of ∼50kDa.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Digest of mAb and seperation of Fab fragments and Fc fragments using a Protein A 
column (non-reducing SDS-PAGE) 
 
5.2.5 Preparation of co- crystallization complex 
 
YdgR was purified as described above and was concentrated to 3.5 mg/ml in the size 
exclusion buffer. Monoclonal Fab fragment was added in a ratio of 1:2. The complex 
and YdgR alone eluted at a quite similar elution volume, therefore an excess of mFab 
fragment was added to saturate the binding to YdgR. The sample was loaded on a 
Superdex 200 10/300GL column or a HiLoad Superdex 200 16/60 column (GE 
Healthcare). This rapid size exclusion step was used to create an equimolar complex 
and suitable crystallization sample, in which the excess of monoclonal Fab fragments 
was removed (Figure 5.13).   
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Figure 5.13: a. Size exclusion of YdgR with mFab on HiLoad Superdex 200 16/60 column (YdgR-
mFab complex in rose and mFab alone in blue); b. SDS-PAGE analysis of different fractions. 
 
5.2.6 Co-crystallization trials of YdgR with mFab 5E8-D6 
 
The fractions containing the complex were concentrated to 6.5 mg/ml and used for 
crystal trials. A large number of different commercial 96-well crystal screens were 
used: JBS 1-4 (Jena Bioscience), JBS 5-9 (Jena Bioscience), Cryo 1+2 Crystallization 
Screen (Emerald Biosystems), Crystal Screen (Hampton Research), PGA screen 
(Molecular Dimensions), Index (Hampton Research), Wizard 1+2 (Emerald 
BioSystems), Salt Rx (Hampton Research), MemFac (Hampton Research), PEG 
(Hampton Research), Natrix (Hampton Research) and JBS 9-10 (Jena Bioscience).  
For the complex of YdgR with 5E8-D6, two hits could be observed after 3 weeks in 
the Cryo 1+2 Crystallization Screen (Emerald Biosystems) in condition A6 (100 mM 
Cacodylate pH 6.5; 40% PEG 600; 0.2 M Na-acetate) and H10 (100 mM CAPS pH 
10.5; 30% PEG 200; 200 mM Ammonium sulfate). The crystals in both hits absorbed 
at 280 nm under the UV lamp in a Crystal Hotel imaging system (Rigaku), which 
identified them as protein crystals. Both hits were sent to the ESRF synchrotron in 
Grenoble. The crystals derived from condition H10 did not diffract at all while the 
crystals grown in A6 diffracted to 8-10 Å. To improve diffraction, a 96-well format 
fine screen of condition A6 was set up. The grid screen screened for optimal pH 
(between 5.3 and 7.2) and optimal PEG 600 concentration (32-46%). Best crystals 
could be grown in a pH range of 5.5- 6.2 and a PEG 600 concentration of 36-42% 
(Figure 5.14). Higher pH increased the tendency for precipitation and higher PEG 
concentrations increased the probability for micro-cystals in a shower of crystals. 
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Unfortunately the optimized and larger crystals did not increase diffraction and 
therefore no data better than 8 Å could be collected.  
 
 
Figure 5.14: a. Initial hits of complex of mFab 5E8-D6 with YdgR; b. Optimized crystal conditions 
derived from Cryo1+2 Crystallization Screen 
 
5.2.7 Co-crystallization trials of YdgR with mFab 5E3-F10 
 
For 5E3-F10 different YdgR constructs were used for co-crystallization. Native YdgR 
with a C-terminal His-tag or N-terminal cleaved His-tag was mixed with mFab 5E3-
F10. Additionally, N-terminal cleaved His-tagged S166G and N196K/S166G were 
used together with mFab 5E3-F10 for co-crystallization. These mutants are described 
further in  chapter 5.3. The samples were prepared as described for co-crystallization 
with mFab 5E8-D6.  
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Figure 5.15: a. Initial hit Cryo 1+2 Screen; b. Change in crystal morphology due to pH change; c. 
Optimized crystals sent to ESRF 
 
Crystals could be observed after approximately 2 weeks for the complex between C-
terminal His-tagged native YdgR with mFab 5E3-F10 in the Cryo 1+2 Crystallization 
Screen (Emerald Biosystems) in condition G6 containing 100 mM citrate pH 5.5 and 
40% (v/v) PEG 600 (Figure 5.15 a). Optimization was performed using a 96-well 
format grid screen based on variation of pH and PEG 600 concentration. 
Crystallization seemed be quite dependent on pH. Slight changes in pH generated 
single crystals or a shower of micro-crystals (Figure 5.15 b). Additionally it seemed to 
improve crystal morphology to use drop ratios of protein:reservoir of 2:1 instead of 
1:1. This increased the PEG 600 concentration necessary to induce the crystallization 
process and larger crystals could be generated (Figure 5.15 c).  
 
The crystals were sent to the ESRF synchrotron Grenoble (Figure 5.16), but the 
diffraction was limited to 8-10 Å and therefore no structural information could be 
gained.  
 
 
 
   62 
 
Figure 5.16: a. Crystal mounted at the ESRF; b. and c. Diffraction patter of co-crystal of YdgR with 
mFab 5E3-F10 (condition 100mM citrate pH=5.1; 46% (v/v) PEG 600; 200nl protein:100nl reservoir) 
 
5.3 Thermostable mutants 
5.3.1 Analysis of thermostability of loss-of-function mutants via 
Stargazer 
 
Previous work from our laboratory has identified 35 loss-of-function mutants in YdgR 
using random mutagenesis ([35]; see Appendix). To evaluate the YdgR mutants for 
thermostability we chose to measure protein aggregation by static light scattering, as 
employed by the Stargazer instrument.  In order to determine whether the Stargazer is 
an appropriate method to identify mutants that will show an increase in 
thermostability, the native LacY protein and the thermostable LacY mutant C154G 
were tested as a control and the difference in Tagg was plotted. (Figure 5.17 a) 
Sixteen of the identified 35 YdgR mutants were then purified and tested in the 
Stargazer at two different protein concentrations.  In order to compare the Tagg of the 
mutants to that of native YdgR, the difference in Tagg between the mutant and native 
proteins was calculated (Figure 5.17 b).   
 
Five mutants, N196K, V252E, K274I, A285V, and M295K showed an increase in 
Tagg as compared to native YdgR of more than +2° C.  Repeated testing confirmed 
that N196K, V252E, K274I, M295K showed a reproducible increase in Tagg (Figure 
5.17c). 
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Figure 5.17: a. Differenc in Tagg between Lac Y and C154G b. Summary of differences of Tagg of all 16 
mutants compared with native YdgR ; c. Tagg increase of thermostable mutants 
 
5.3.2 Size exclusion thermostability assay 
 
To further evaluate the thermostability of N196K, V252E, K274I and M295K, these 
mutants were also tested using an alternative thermostability assay.  We developed a 
size exclusion-based assay to assess the amount of protein still folded after incubation 
at high temperature by comparing the size and shape of the proteins’ size exclusion 
peak after incubation at 4° C and 50° C.  The thermostable mutants are expected to 
show a higher amount of folded protein remaining after this treatment in comparison 
to the native protein.  Again, LacY and the C154G mutant were used as controls in 
the size exclusion assay.  While native LacY shows a clear decrease in the amount of 
folded protein remaining after incubation at 50° C, the C154G mutant is completely 
stable, and shows no decrease in peak size (Figure 5.18). 
 
 
Figure 5.18: Size exclusion profile of LacY and LacY C154G incubated for 5vminutes at 4°C (dark 
blue) or 50°C (red) 
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Next, the native YdgR protein and the mutants were incubated at 4° C and 50° C and 
loaded onto the Superdex 200 size exclusion column.  Native YdgR incubated at 4° C 
shows a sharp peak while the incubation at 50° C does not change the shape of the 
peak, but dramatically reduces the fraction of folded protein (Figure 5.19).  For the 
mutants identified as more stable in the Stargazer assay, exclusively N196K showed 
increased thermostability in the size exclusion assay (Figure 5.19).  The fraction of 
folded protein after incubation at 50°C was increased  from 38% to 50% as compared 
to native YdgR and no aggregates were observed. The V252E mutant also shows a 
homogenous and sharp peak after the incubation at 4°C, but the high temperature 
treatment dramatically reduces the fraction of folded protein (Figure 5.19).  The 
K274I and M295K mutants show an extensive reduction in the folded portion of 
protein even after incubation at 4°C (Figure 5.19).  Additionally aggregates could be 
observed that were not detected for the native protein.  
Since it has been proposed that mutations to alanine are most likely to increase 
thermostability [52], the N196A mutant was generated and also tested in the size 
exclusion assay.  After incubation at 50° C the mutant shows stability comparable to 
native YdgR.  No increase in thermostability could be observed (Figure 5.19). 
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Figure 5.19: Size exclusion profiles of WT and mutants incubated for 5 minutes at 4°C (dark blue) or 
50°C (red); K274I and M295K incubated for 5 minutes at 4°C (light blue) in comparison with WT after 
5 minutes on 4°C (dark blue) 
 
Generation of a homology model between LacY and YdgR [35] revealed the residue 
S166 to be in an equivalent position to C154 of LacY.  Therefore the YdgR mutant 
S166G was generated in order to characterize its thermostability.  The S166G mutant 
shows an increase in the amount of folded protein remaining after incubation at 50° 
C, but seems to be slightly less thermostable than N196K (Figure 5.20).  
The double mutant S166G/N196K was also generated and tested to determine 
whether the effect of both mutations would be additive.  The double mutant shows an 
increase in thermostability as compared with native YdgR and the single mutants 
(Figure 5.20).  
The peak area of folded protein after incubation at 4°C and 50°C were compared and 
plotted in a graph as fraction of folded protein (%) after partial thermal unfolding. 
While the WT showed a reduction to ∼38% folded protein, for the mutants S166G, 
N196K and the double mutant an increase to ∼42-55% of folded protein could be 
observed. For the double mutant approximately 55% are still properly folded after 5 
minutes at 50°C.  
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This stabilizing effect was compared with LacY and the thermostable mutant C154G. 
The fraction of folded LacY was reduced to ∼50% by thermal stress while more or 
less all of C154G kept its stable and folded conformation after incubation at 50°C. 
Compared with S166G, which is supposed to be in an equivalent position in YdgR, 
C154G showed a much more dramatic improvement of thermostability (Figure 5.20). 
 
 
Figure 5.20: Graph (a)  and Table (b)  fraction of folded protein (%)  
 
Additionally the thermostability of PepTso was tested with this assay. As mentioned 
above, PepTso is a prokaryotic homolog of the mammalian peptide transporters from 
Shewanella oneidensis. PepTso was crystallized and the structure was solved in 2010 
[39]. This assay allowed the comparison of thermostability of the E. coli homolog 
YdgR with the Shewanella oneidensis homolog PepTso of mammalian peptide 
transporters. For PepTso, ∼84% of the protein remained folded while for YdgR only 
∼38% of folded protein could be detected (Figure 5.20, Figure 5.21).  
 
       
Figure 5.21: Gel filtration profile of YdgR WT and PepTso 
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5.3.3 CPM assay  
 
A major question concerning the crystallizability of membrane proteins is the stability 
of membrane protein targets in different detergents, since short length detergents 
seem to be better able to support the formation of well diffracting crystals [36] but 
often are not tolerated by membrane proteins.  Therefore we tested the stability of 
S166G, N196K and S166G/N196K in different detergents (DDM, NTM and LDAO) 
using a CPM fluorescence-based thermostability assay [3; 57].  This assay is based on 
the interaction of the thiol-reactive fluorescent dye CPM with cysteine residues, 
which should be deeply buried within the protein, but which become accessible 
during the unfolding process.  The native and mutant proteins were diluted 100-fold 
into a new detergent and the change in fluorescence was monitored over 150 minutes 
during incubation at 40° C.  The fraction of folded protein remaining at each time 
point was calculated and graphed (Figure 5.22 a).    
 
 
Figure 5.22: a. Fraction of folded protein of native YdgR and thermostable mutants plotted against 
time; b. Fraction of folded protein of native YdgR, thermostable mutants and PepTso plotted against 
time 
 
For incubation in the detergent LDAO a clear difference between the native protein 
and the mutants is visible, and the half-life is approximately doubled.  The double 
mutant shows a similar effect but surprisingly the degree of stabilization is 
comparable to the single mutants and not increased, as suggested by the gel filtration 
data.  
When the result of the CPM assay with native YdgR and the mutants were compared 
with the fraction of folded PepTso in LDAO (Figure 5.22 b), it was observed that 
PepTso has a 9 to 10 times longer half-life in LDAO as compared with the 
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thermostable YdgR mutants. Both the higher thermostability and the higher tolerance 
to short length detergents of PepTso compared to YdgR could make it a better 
potential candidate for crystallization.  
 
5.3.4 Examination of transport activity of the thermostable mutants 
 
While the N196K mutant has been previously characterized and has been shown to 
have a partial loss of transport activity [35], the S166G mutant has not been 
characterized.  Therefore the mutants were characterized regarding membrane 
localization and transport activity using two different transport assays.  Since the 
mutant Y156A is known to be inactive [65] it was used as a control in the transport 
assays.  Membrane localization was tested by analysis of equal concentrations of 
membrane fractions by Western blot.  All constructs are expressed in equal amounts 
and are suitable for comparison of transport activity in living cells (Figure 5.23). 
 
Figure 5.23: Western Blot of membrane fractions (exposure time 10 seconds) 
 
Transport was first tested by growth in the presence of the antibiotic alafosfalin, 
which is a specific substrate of YdgR [9].  Bacteria expressing the functional 
transporter will die while those possessing an inactive transporter can grow without 
inhibition.  When bacteria expressing each construct are grown without alafosfalin, no 
reduction of growth rate can be observed for native YdgR, the empty vector, or any of 
the mutants (Figure 5.24 a).  When this growth assay is carried out in the presence of 
alafosfalin the growth rate of native YdgR is reduced after induction, due to 
expression of the functional transporter, while there is no inhibition of growth for 
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bacteria expressing the empty vector or the non–functional mutant Y156A.  S166G, 
N196K as well as the double mutant S166G/N196K show a clear growth advantage as 
compared to native YdgR (Figure 5.24 b).  Therefore all of these mutants are unable 
to take up alafosfalin.  
 
 
Figure 5.24: Growth assay performed without (a) or with (b) alafosfalin 
 
Next, the uptake of β-Ala-Lys (AMCA), a dipeptide covalently bound to a fluorescent 
moiety, was tested (Figure 5.25).  Native YdgR clearly shows uptake of this peptide 
while no increase in fluorescence is observed for bacteria expressing the empty vector 
or the non-functional mutant Y156A.  The transport activity of S166G for β-Ala-Lys-
AMCA was reduced dramatically while the mutant N196K shows partial transport 
activity.  This activity is reduced in the double mutant to a value comparable to that of 
S166G.  Data from both assays indicates that S166G and the double mutant are non – 
functional transporters while N196K shows some ability to transport β-Ala-
Lys(AMCA).  
                 
Figure 5.25: Uptake of  β-Ala-Lys(AMCA). The transport of WT YdgR was set to 100%. 
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5.3.5 Crystallization trials with thermostable mutants 
 
Crystal trials of S166G, N196K and the double mutant were set up. Unfortunately no 
crystals could be observed. 
 
5.3.6 Thermostable mutants adopt a single conformation 
 
As mentioned in chapter 5.2.3 one of the monoclonal antibodies generated for co-
crystallization purpose is unable to recognize the mutants S166G and N196K, as 
shown by the lack of complex formation during gel filtration chromatography (Figure 
5.10).  As neither residue is predicted to be localized in an extramembrane loop, this 
suggests that these mutations cause the transporter to preferentially adopt a single 
conformation in which the antigen binding site is altered and is thereby inaccessible to 
the antibody. 
 
In order to investigate this phenomenon further, we performed acetylation of 
accessible lysines coupled to mass spectrometry analysis to identify lysine residues in 
YdgR that show altered accessibility between the native transporter and the N196K 
and S166G mutants. This experiment was repeated several times and the digest for 
mass spectrometry was performed with either chymotrypsin or subtilisin to reach high 
sequence coverage. The reproducible differences in accessibility of lysines of native 
YdgR and the mutants were localized in the YdgR homology model [35] to determine 
their position.  
Five lysine residues repeatedly show a difference in acetylation in the comparison 
between native YdgR and the thermostable mutants. Most interesting, only one of 
them, namely K177, is predicted to be located in a periplasmatic loop while the others 
are close to the cytoplasmic side. Additionally this loop shows a dramatic difference 
in lysine accessibility. While the average acetylation of K177 was 0.4% for the wild- 
type, this value drops to zero for the thermostable mutants (Figure 5.26). That would 
mean that at least part of the loop between Helix 5 and 6 is not accessible for 
acetylation in the thermostable mutants, suggesting that the mutants are locked in the 
inward-facing conformation, burying the loop between Helix 5 and 6. Another lysine 
residue that showed a quite drastic difference in lysine acetylation pattern is K131. 
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While this residue is highly accessible in S166G, the wild-type and N196K proteins 
show a reduced average lysine acetylation. This could be due to different mechanisms 
of locking the mutant in one conformation. In general the lysine acetylation pattern of 
N196K is quite similar to the native YdgR with the exception of K177. S166G shows 
generally an abberant average acetylation pattern when compared to native YdgR. 
Generally the lysine residues close to the cytoplasmic side show higher accessibility 
while the residue in the periplasmatic loop was completely buried.  
In order to confirm this data and determine whether the mutants are indeed locked in 
the inward-facing conformation, we plan to design cysteine mutants of the potential 
periplasmic gating residues Glu 56 and Arg  305 inYdgR [35]. They should approach 
in the inward-facing conformation but their distance is increased in the outward- 
facing conformation. Cystein- crosslinkers of different length will be used to test the 
distance of these mutants in native YdgR and the mutants S166G and N196K. 
Cysteine cross-linking was also used to determine the gating residues of Lac Y [67; 
69].  
 
Figure 5.26: Summary of differences in lysine acetylation pattern 
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6 Discussion 
 
YdgR is a prokaryotic member of the Peptide Transporter (PTR) family. This family 
is driven by a proton gradient and is widespread throughout all organisms from 
bacteria to man [9]. This prokaryotic transporter was chosen as a good candidate to 
study this family of transporters as well as to test two strategies to facilitate 
crystallization since formation of well-ordered crystals is still a major bottleneck in 
studies on integral transmembrane transporters.  
 
6.1 Crystallization trials of native YdgR gave rise to 
unreproducible crystals 
 
Crystallization trials of the native target protein gave rise to crystals diffracting to 10 
Å. This poor diffraction is typical for 3D Type 2 crystals, especially for integral 
membrane proteins that do not have large soluble domains. The crystal contacts are 
then solely made by small accessible areas that are not covered by the detergent 
micelle. Contacts between the polar head groups of the detergent molecules of 
neighboring proteins can also support crystal formation, but contribute poorly to 
protein ordering in the crystal since the interactions are unspecific [43].  
 
In addition to diffracting poorly, the crystals could not be reproduced. Since crystal 
formation is dependent on many different components and environmental influences, 
it is hard to determine the variables responsible for failed crystal formation. For the 
crystallization of the native lactose permease LacY, it was shown that E. coli 
phospholipid extracts were necessary for successful crystallization [20]. The 
solubilization of the target protein from the membrane with detergent does not result 
only in protein-detergent micelles, but also lipids are co-extracted from the 
membrane. Therefore every purification step can also be regarded as a delipidization 
step. Co-extracted lipids are removed to a different extent depending on the 
purification strategy. The effect of varying amounts of co-solubilized lipids resulting 
from different purification strategies and their effect on crystal quality could be 
observed for the glycerol-3-phosphate transporter GlpT [33].  
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In addition to lipid content, detergent content of the protein sample can vary from 
batch to batch and therefore the sample may or may not give rise to crystals [20]. The 
role of detergent content in the crystallization of membrane protein samples is known 
for quite some time. For bacteriorhodopsin it was shown that crystallization only 
occurred in drops where phase separation of high or low content detergent phases was 
prevented [36]. For crystallization of porins the high content detergent phase was 
necessary to give rise to crystals [36]. For other membrane proteins such as the 
glycerol-3-phosphate transporter GlpT, a too high content of detergent prevented 
crystallization [33].  
Therefore slight changes in detergent or lipid content, resulting from different batches 
of purified protein seems to prevent crystallization. This might be true in the case of 
YdgR, since the crystals could only be grown and optimized with one specific batch 
of protein. However, relipidization and addition of E.coli lipid extract before 
crystallization trials of YdgR did not support crystal formation.  
 
6.2 Two antibodies against YdgR were generated  
 
Two monoclonal antibodies against a truncated version of native YdgR were 
generated successfully. Both antibodies interact with a conformationally intact 
epitope, which was proven with positive ELISA and negative Western blot results.  
Antibody 5E8-D6 interacts with an epitope that is only accessible in native YdgR. 
This epitope is not recognized in the thermostable mutants S166G and N196K. 
Additionally, this epitope seems to be blocked by a C-terminal His-tag, since no 
interaction with the antibody can be observed for C-terminal His-tagged YdgR while 
there is a clear antibody-antigen peak visible on size exclusion for N-terminal His-
tagged protein (Figure 5.10) independent of tag-removal with TEV protease. 
Therefore the epitope is suspected to be near the C-terminal His–tag. The YdgR 
homology model based on the structures of LacY and PepTso [35] shows that the C-
terminus and the N-terminus of YdgR are located at the cytoplasmic side of the 
membrane.  
 
Since YdgR reconstituted into proteoliposomes was used for immunization, it is 
rather likely that the epitope is part of an easily accessible loop region rather than of a 
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most probably buried helical part. The epitope of 5E8-D6 is presumably located in a 
loop in proximity of the C-terminus. Interaction of the antibody with the loop between 
helix 8 and 9 seems to be rather unlikely since residues in this region were identified 
to be more accessible for acetylation of lysine residues 343 and 353 in the 
thermostable mutants  (Figure 5.26). Therefore the epitope recognized by 5E8-D6 is 
most likely located in the connecting loops between helix HB and 7 or helix 10 and 
11 (Figure 6.1b). In comparison of the LacY inward-facing structure and the PepTso 
inward-facing occluded structure [39], helices 7, 11 and 12 form a helix bundle that is 
displaced by an 11° rotation during the conversion from the inward-facing occluded 
state to the inward-facing conformation. This ‘C1-helix bundle’ is suspected to 
undergo the largest displacement during transport (Figure 6.1a). Since PepTso has 
over 45% homology to YdgR [35], it can be hypothesized that the role of this C1-
helix bundle is conserved, and that the epitope is located within the boundaries of this 
area or the rest of the C-bundle. Therefore the epitope is not accessible anymore when 
the protein is caught in a conformation specific for the thermostable mutants, while 
native YdgR is still able to flip between different conformations and exposes this 
epitope.  
 
      
Figure 6.1: Cytoplasmic view of the YdgR homology model based on the structures of LacY and 
PepTso [35]; Left: N-terminal and C-terminal helix bundles as assigned for PepTso (See figure X); 
Right: Loops potentially containing 5E8-D6 epitope; Lysine 343 and 353 in yellow 
 
Antibody 5E3-F10 recognizes native YdgR as well as the thermostable mutants. 
Therefore the epitope must be accessible in the outward and the inward-facing 
conformation in the native as well as in the thermostable mutants of YdgR. 
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6.3 Co-crystallization with mFab fragments resulted in 
crystals diffracting to 8-10 Å 
 
Proteolytically generated Fab fragments were used for co-crystallization trials with 
YdgR. Complexes of YdgR with mFab fragments of both antibodies gave rise to 
crystals diffracting to 8-10 Å. Optimization was performed but did not improve 
diffraction. The location of the epitope and the quality of the crystal contacts formed, 
will determine the diffraction quality of the crystals. If the interaction area of the 
target protein with the mFab is still rather flexible this may inhibit crystallization or 
give rise to crystals that are not suitable for structure determination. This cannot be 
tested before crystallization trials and therefore several monoclonal antibodies that are 
used to generated mFab fragments are required for co-crystallization trials. 
Unfortunately the two generated antibodies specific for YdgR did not give rise to 
well-diffracting crystals.  
 
6.4 Two mutants with increased thermostability could be 
identified 
 
Four thermostable mutants were identified from 16 loss-of-function mutants with the 
Stargazer instrument. Surprisingly, only one of those mutants was confirmed to be 
more thermostable with a second assay. Two of the false positive mutants, namely 
K274I and M295K, showed heavy precipitation when incubated at 4°C and analyzed 
via size exclusion chromatography (Figure 5.19). The other mutant V252E shows a 
decreased fraction of folded protein after incubation at 50°C in comparison with 
native YdgR. These results suggest that initial precipitation of the target protein in the 
high-throughput Stargazer assay may reduce the concentration of soluble protein, 
which may artificially raise the measured aggregation temperatures, leading to a false 
positive result. We also observed that reduction of protein concentration increased the 
aggregation temperature (Figure 5.17). Therefore additional proof for increased 
thermostability is absolutely necessary as a second step after screening with 
Stargazer.  
The only mutant resulting from the Stargazer screen confirmed to be more 
thermostable is N196K. Most interesting, the mutant homologous to C154G in LacY, 
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namely S166G, is also more thermostable than native YdgR. Therefore it seems 
possible to engineer mutants comparable with already described mutants, as has also 
been shown for G-protein coupled receptors [53]. This technique could be used for 
other proteins to facilitate crystallization or to lock them in one conformation.  
Unfortunately, the effect of the double mutant S166G/N196K was not additive, but 
rather only increased very slightly in comparison with the single mutations. (Figure 
5.20) 
It was shown for LacY that C154 forms hydrogen bonds with the backbone of helix 1, 
which might be crucial for the cooperativity of the transport mechanism. Mutagenesis 
to glycine suggests less intimate contact beween helices 1 and 5 [20]. This might be 
true as well for S166G in YdgR. N196 is located in helix 6, closer to the cytoplasmic 
side, and may also form interactions with helix 1 (Figure 6.2). The mutation to lysine 
may also hinder the close contact of helix 6 and helix 1 within the N-terminal helix 
bundle.  
  
Figure 6.2: Homology model of YdgR showing the side-chains of S166 (blue) and N196 (magenta) 
 
6.5 Thermostability and tolerance for harsh detergents of 
YdgR mutants in comparison with PepTso  
 
As mentioned previously, the structure of PepTso from Shewanella oneidensis was 
solved in 2011 [39]. No structure of a member of the PTR family had previously been 
determined. Our studies on strategies to facilitate the crystallization of the E. coli 
homologue YdgR was ongoing when the PepTso structure was published. Therefore it 
was of high interest to determine whether PepTso shows increased resistance to 
thermal stress when compared to native YdgR and the thermostable mutants, since it 
has been proposed that increased thermostability goes hand in hand with 
crystallizability [34; 52]. As described in section 5.3.2, PepTso shows increased 
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thermostability when compared to native YdgR (Figure 5.20 and 5.21). While 
approximately 38% of YdgR is still folded after incubation at 50°C, 84% of PeptTso 
remains intact and folded. Even the thermostable YdgR mutants are less thermostable 
than PepTso, despite their selection for thermostability, since the maximum percent of 
folded protein that could be reached was 55%. Additionally, PepTso shows increased 
tolerance for the harsh detergent LDAO, increasing the stability 10-fold in 
comparison with YdgR. Increased stability in LDAO was described as a ‘benchmark’ 
for crystallizability [57]. Our results with YdgR support this conclusion and also 
suggest the hypothesis that a certain threshold of thermostability and tolerance for 
harsh detergents is necessary for a target membrane protein to crystallize (Figure 6.3).  
 
 
Figure 6.3: a. Result of size exclusion thermostability assay; b. Stability of YdgR and thermostable 
mutants in LDAO in comparion with PepTso 
 
6.6 Thermostable mutants are most likely locked in one 
conformation 
 
The acetylation of accessible lysine residues followed by the analysis of the 
acetylation pattern via mass spectrometry shows that the thermostable mutants S166G 
and N196K are most probably locked in the inward-facing conformation. The lysine 
residue K177 in the loop between helices 5 and 6 on the periplasmic side was not 
accessible to acetylation in the thermostable mutants, suggesting more limited 
accessibility on the periplasmic side. For S166G the lysine residues are generally 
more accessible than observed for native YdgR (Figure 5.26). The values of average 
acetylation for N196K are comparable with native YdgR for the lysine residues on the 
cytoplasmic side, except for the lysine residue 482 at the C-terminus following helix 
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12. This residue is more accessible in N196K as well as in S166G when compared to 
native YdgR. This suggests that helix 12 is rather straightened in the thermostable 
mutants. Since helix 12 is part of the proposed ‘C1 sub-bundle’, straightening of this 
helix may be an additional indication that the thermostable mutants predominantly 
adopt the inward-facing conformation, resulting in reduced transport activity as 
observed for the thermostable mutants. Nevertheless, this result has to be confirmed 
with additional experiments.  
Especially because the structure of the LacY mutant C154G was solved in the inward-
facing conformation while biochemical studies in membrane vesicles suggest that 
C154G is locked in the outward-facing conformation [40]. 
 
6.7 Lessons learned from YdgR to facilitate cystallization of 
integral membrane proteins 
 
Structure determination of YdgR failed due to poorly diffracting crystals and the low 
reproducibility of crystals, which made attempts at optimization difficult. Two 
strategies to facilitate crystallization were tested including co-crystallization with 
mFab fragments and identification of thermostable mutants. Co-crystallization with 
mFab fragments seems to be quite promising but is costly and time-consuming. 
Additionally several mAbs have to be cleaved and tested to identify the mFab 
fragment with optimal characteristics for co-crystallization and structure 
determination. If the epitope is too flexible, the antibody-antigen complex will still 
give rise to poorly diffracting crystals.  
 
Selection for thermostable mutants appears to be a promising strategy as well. It was 
shown for G-protein coupled receptors that alanine-scanning mutagenesis [52] as well 
as random mutagenesis [10; 48] can improve receptor expression, stability in various 
detergents and alter binding selectivity. Resulting mutants are suitable targets for 
crystallization attempts as several crystal structures of engineered GPCRs have been 
solved [11; 32; 60]. Alanine-scanning mutagenesis is rather time-consuming while 
random mutagenesis seems to be a straightforward tool to generate promising 
mutants. The combination of random mutagenesis with a functional assay, seems to 
be especially suitable for selection of mutants showing high tolerance for detergents 
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and preference for agonist or antagonist conformations due to reduced conformational 
flexibility [31; 34]. It should also be possible to apply this screening method to other 
membrane proteins with lower binding affinities than GPCRs.  
 
For YdgR, random mutagenesis followed by a transport assay was coupled with a 
thermostability and detergent screen. The thermostability screen and the detergent 
screen can be applied to every membrane protein target.  
Single point mutations in YdgR increased thermostability and tolerance for the harsh 
detergent LDAO, making them a better target for crystallization experiments. But 
when compared to the homologue PepTso whose structure was solved, the stabilizing 
effect is still quite low. Therefore screening for the optimal homologue for 
thermostability or detergent tolerance seems to be fundamental to identify suitable 
targets for crystallization trials.  
Additionally there seems to be a certain threshold of thermostability and tolerance for 
harsh detergents absolutely necessary for successful crystallization attempts. PepTso 
and LacY C154G show a fraction of 80-90% of folded protein after incubation at 
50°C, while the thermostable YdgR mutants do not exceed values of 56%. Most 
probably the stabilization effect of the mutants is not high enough to promote 
crystallization. Additional point mutations may be necessary to increase 
thermostability for production of a suitable crystallization target.  
Nevertheless high-throughput screening via the Stargazer or CPM assay could help to 
identify novel targets for crystallization of transporters and help to evaluate the 
necessary stabilization for engineered mutants, especially when the number of 
homologues is limited.  
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